WO2017211303A1 - Novel heterocyclic derivatives useful as shp2 inhibitors - Google Patents
Novel heterocyclic derivatives useful as shp2 inhibitors Download PDFInfo
- Publication number
- WO2017211303A1 WO2017211303A1 PCT/CN2017/087471 CN2017087471W WO2017211303A1 WO 2017211303 A1 WO2017211303 A1 WO 2017211303A1 CN 2017087471 W CN2017087471 W CN 2017087471W WO 2017211303 A1 WO2017211303 A1 WO 2017211303A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- amino
- substituted
- compound
- membered
- Prior art date
Links
- 0 **(CC1)CCC11C2(CC2)COC1 Chemical compound **(CC1)CCC11C2(CC2)COC1 0.000 description 3
- HTSHEESMNDUNOR-UHFFFAOYSA-N C(C1)CN(C2)C1CC21CCNCC1 Chemical compound C(C1)CN(C2)C1CC21CCNCC1 HTSHEESMNDUNOR-UHFFFAOYSA-N 0.000 description 1
- SRABNYDKYIKAOS-UHFFFAOYSA-N C1C(C2)C1CC21CCNCC1 Chemical compound C1C(C2)C1CC21CCNCC1 SRABNYDKYIKAOS-UHFFFAOYSA-N 0.000 description 1
- FOQMVSXASSTLEH-UHFFFAOYSA-N CN(C)C(C(c1cccc(NC(N)=O)c1)=O)=O Chemical compound CN(C)C(C(c1cccc(NC(N)=O)c1)=O)=O FOQMVSXASSTLEH-UHFFFAOYSA-N 0.000 description 1
- ZEBZKXGVJPCCCM-UHFFFAOYSA-N CNC(Nc(cc1)ccc1C(C(N(C)C)=O)=O)=O Chemical compound CNC(Nc(cc1)ccc1C(C(N(C)C)=O)=O)=O ZEBZKXGVJPCCCM-UHFFFAOYSA-N 0.000 description 1
- SGJFSBWAHVPAAM-UHFFFAOYSA-N CNC(c(cc1)ccc1C(C(N(C)C)=O)=O)=O Chemical compound CNC(c(cc1)ccc1C(C(N(C)C)=O)=O)=O SGJFSBWAHVPAAM-UHFFFAOYSA-N 0.000 description 1
- FHYZKTLSTZDJFW-UHFFFAOYSA-N CNC(c1cc(C(C(N(C)C)=O)=O)ccc1)=O Chemical compound CNC(c1cc(C(C(N(C)C)=O)=O)ccc1)=O FHYZKTLSTZDJFW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Definitions
- This invention relates to certain novel pyrazine derivatives (Formula I) as SHP2 inhibitors which is shown as formula I, their synthesis and their use for treating a SHP2 mediated disorder. More particularly, this invention is directed to fused heterocyclic derivatives useful as inhibitors of SHP2, methods for producing such compounds and methods for treating a SHP2-mediated disorder.
- SHP2 The Src Homolgy-2 phosphatease
- SHP2 is a non-receptor protein tyrosine phosphatase encoded by the PTPN11 gene that harbors a classical tyrosine phosphatase domain and two N-terminal Src homology 2 (SH2) domains and a C-terminal tail.
- SH2 N-terminal Src homology 2
- the two SH2 domains control the subcellular localization and functional regulation of SHP2.
- the N-terminal SH2 domain blocks the PTP domain and this autoinhibition is relieved by binding of the SH2 domains to specific phosphotyrosine sites on receptors or receptor-associated adaptor proteins.
- the stimulation for example, by cytokines or growth factors leads to exposure of the catalytic site resulting in enzymatic activation of SHP2.
- SHP2 is widely expressed and participated in multiple cell signaling processes, such as the Ras-Erk, PI3K-Akt, Jak-Stat, Met, FGFR, EGFR, and insulin receptors and NF-kB pathways, in which plays an important role in proliferation, differentiation, cell cycle maintenance and migration.
- the hyperactivation of SHP2 catalytic activity caused by either germline or somatic mutations in PTPN11 has been identified in patients with Noonan syndrome, Leopard syndrome, juvenile myelomonocytic leukemias, myelodysplastic syndrome, B cell acute lymphoblastic leukemia/lymphoma, and acute myeloid leukemia.
- activating mutations of PTPN11 have been found in solid tumors as well, such as lung cancer, colon cancer, melanoma, neuroblastoma, and hepatocellular carcinoma. Therefore, the presence of the activated or up-regulated SHP2 protein in human cancers and other disease make SHP2 an excellent target for development of novel therapies.
- the compounds of the present invention fulfill the need of small molecules in order to inhibit the activity of SHP2.
- the present invention relates to heterocyclic pyrazine compounds useful as SHP2 inhibitors and for the treatment of conditions mediated by SHP2.
- the compounds of the invention have the general structure as Formula I or a pharmaceutically acceptable salt:
- Y 1 is N or CR 1 ;
- Y 2 is N or CR 2 ;
- each R 1 and R 2 is independently -H, halogen, -CN, -OH, -NH 2 , -N 3 , -NO 2 , substituted or unsubstituted C 1-6 alkoxy, or substituted or unsubstituted C 1-6 alkyl; or
- each G is independently C 6-10 ary, C 3-8 carbocyclic or C 5-10 heteroaryl; and each of which may be optionally substituted;
- R 5 is -H, halogen, -CN, -OH, -NR 8 R 9 , -N 3 , -NO 2 , C 1-6 alkyl, C 1-6 alkoxy, C 6-10 aryl, C 6-10 arylalkyl, C 6-10 heteroaryl, C 5-18 heterocyclic or C 5-18 carbocyclic; and each of which is independently optionally substituted;
- each R 8 and R 9 is independently -H, halogen, -CN, -OH, -N 3 , -NO 2 , C 1-6 alkyl, C 1-6 alkoxy, C 2-6 alkenyl, NH (C 1-6 alkyl) , N (C 1-6 alkyl) 2 , C 5-10 heterocyclic or C 5-10 carbocyclic; and each of which may be independently optionally substituted.
- the present invention further provides some preferred technical solutions with regard to compound of Formula (I) .
- R 1 is -H, -F, -Cl, -Br, -I, -CN, -OH, -NH 2 , substituted or unsubstituted C 1-3 alkoxy, or substituted or unsubstituted C 1-3 alkyl.
- R 1 is -H, -F, -Cl, -NH 2 , methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy; and each methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy is independently optionally substituted with halogen, OH or NH 2 .
- R 2 is -H, -F, -Cl, -Br, -I, -CN, -OH, -NH 2 , substituted or unsubstituted C 1-3 alkoxy, or substituted or unsubstituted C 1-3 alkyl.
- R 2 is -H, -F, -Cl, -NH 2 , methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy; and each methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy is independently optionally substituted with halogen, OH or NH 2 .
- each G is independently 6-membered aryl, 7-membered aryl, 8-membered aryl, 3-membered carbocyclic, 4-membered carbocyclic, 5-membered carbocyclic, 6-membered carbocyclic or 7-membered carbocyclic; and each of which may be optionally substituted with halogen, -CN, -OH, -NH 2 , -N 3 , -NO 2 , substituted or unsubstituted C 1-6 alkyl, or substituted or unsubstituted C 1-6 alkoxy.
- each G is independently 6-membered aryl, 7-membered aryl, 8-membered aryl, 3-membered carbocyclic, 4-membered carbocyclic, 5-membered carbocyclic or 6-membered carbocyclic; and each of which may be optionally substituted with -F, -Cl, -Br, -CN, -OH, -NH 2 , -NO 2 , substituted or unsubstituted C 1-3 alkyl, or substituted or unsubstituted C 1-3 alkoxy.
- each G is independently phenyl, and which may be optionally substituted with -F, -Cl, -OH, -NH 2 , methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy; and each methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy is independently optionally substituted with -F, -Cl, -Br or -I.
- each G is independently 5-membered heteroaryl, 6-membered heteroaryl, 7-membered heteroaryl or 8-membered heteroaryl; and each of which contains 1, 2, 3 or 4 heteroatoms select from N, O or S, and may be optionally substituted with halogen, -CN, -OH, -NH 2 , -N 3 , -NO 2 , substituted or unsubstituted C 1-6 alkyl, or substituted or unsubstituted C 1-6 alkoxy.
- p is 0 or 1.
- q is 1 or 2.
- R 3 is -NH 2 , or
- R 1 is combines with R 3
- R 4 is -Cl, -NH 2 , methyl or piperidinyl, wherein the ring system is optionally substituted with methyl, -NH 2 or -CH 2 NH 2 .
- the C 6-9 heteroaryl contains 1, 2, 3 or 4 heteroatoms select from N, O or S
- the C 6-9 heteroaryl is 6-membered heteroaryl, 7-membered heteroaryl, 8-membered heteroaryl or 9-membered heteroaryl
- the C 6-17 heterocyclic contains 1, 2, 3, 4, 5, or 6 heteroatoms select from N, O, or S
- the C 6-17 heterocyclic is 6-membered heterocyclic, 7-membered heterocyclic, 8-membered heterocyclic, 9-membered heterocyclic, 10-membered heterocyclic, 11-membered heterocyclic, 12-membered heterocyclic, 13-membered heterocyclic, 14-membered heterocyclic, 15-membered heterocyclic, 16-membered heterocyclic or 17-membered heterocyclic.
- R 5 is -F, -Cl, -Br, -NR 8 R 9 , methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, 6-membered aryl, 7-membered aryl, 8-membered aryl, 9-membered aryl, 6-membered arylalkyl, 7-membered arylalkyl, 8-membered arylalkyl, 9-membered arylalkyl, 6-membered heteroaryl, 7-membered heteroaryl, 8-membered heteroaryl, 9-membered heteroaryl, 6-membered heterocyclic, 7-membered heterocyclic, 8-membered heterocyclic, 9-membered heterocyclic 10-membered heterocyclic, 11-membered heterocyclic, 12-membered heterocyclic, 13-membered heterocycl
- R 5 is each R 21 and R 22 is independently halogen, C 1-3 alkyl, -NH 2 , -C 1-3 alkylene-NH 2 , -C 1-3 alkylene-NH-C 1-3 alkyl, -C 1-3 alkylene-N (C 1-3 alkyl) 2 , -NHBoc or -CH 2 NHBoc;
- X is O, S or absent.
- Y 1 is N and Y 2 is CR 2 .
- Y 2 is N and Y 1 is CR 1 .
- R 4 is -NH 2 .
- R 5 is -NH 2 , or
- each R 8 and R 9 is independently -H, halogen, CN, -OH, -NO 2 , -NH 2 , -C 1-6 alkylene-NH 2 , -C 1-6 alkylene-NH-C 1-6 alkyl, -C 1-6 alkylene-N (C 1-6 alkyl) 2 , -NHBoc, -CH 2 NHBoc; -NH-C 1-6 alkyl, -N (C 1-6 alkyl) 2 , -NH-C 1-6 alkoxy, -N (C 1-6 alkoxy) 2 , C 1-6 alkyl, C 1-6 alkoxy, C 2-6 alkenyl, C 2-6 alkylnyl, C 5-10 heterocyclic or C 5-10 carbocyclic; each of which may be optionally substituted.
- each R 8 and R 9 is independently -H, -F, -Cl, -CN, -OH, -NO 2 , -NH 2 , -C 1-3 alkylene-NH 2 , -C 1-3 alkylene-NH-C 1-3 alkyl, -C 1-3 alkylene-N (C 1-3 alkyl) 2 , -NHBoc, -CH 2 NHBoc; -NH-C 1-3 alkyl, -N (C 1-3 alkyl) 2 , -NH-C 1-3 alkoxy, -N (C 1-3 alkoxy) 2 , C 1-4 alkyl, C 1-3 alkoxy, C 2-3 alkenyl, C 2-3 alkylnyl, 5-membered heterocyclic, 6-membered heterocyclic, 7-membered heterocyclic, 8-membered heterocyclic, 9-membered heterocyclic, 10-membered heterocyclic, 5-membered
- the compound is of Formula II:
- X is absent or S
- Y 1 is N or CR 25 ;
- Y 2 is N or C
- R 25 is H, halogen, C 1-3 alkyl, C 1-3 alkoxy, C 2-3 alkenyl or C 2-3 alkylnyl;
- ring is 5-8 member heteUoaryl containing 1, 2, 3 or 4 heteroatoms select form N, O or S, 5-8 member carbocyclic or 5-8 member heterocyclic ring containing 1, 2, 3 or 4 heteroatoms select form N, O or S;
- n 0, 1, 2, 3 or 4;
- R 4 is -H, halogen, -NH 2 , substituted or unsubstituted C 1-3 alkoxy, or substituted or unsubstituted C 1-3 alkyl;
- each R 32 and R 33 is independently -H, halogen, -OH, -NH 2 , -CN, -NO 2 , -C 1-3 alkylene-NH 2 , -C 1-3 alkylene-NH-C 1-3 alkyl, -C 1-3 alkylene-N (C 1-3 alkyl) 2 , -NHBoc, -CH 2 NHBoc; -NH-C 1-3 alkyl, -N (C 1-3 alkyl) 2 , -NH-C 1-3 alkoxy, -N (C 1-3 alkoxy) 2 , substituted or unsubstituted C 1-3 alkyl, or substituted or unsubstituted C 1-3 alkoxy;
- the present invention further provides some preferred technical solutions with regard to compound of Formula (II) .
- ring is 5-membered heteroaryl, 6-membered heteroaryl, 7-membered heteroaryl, 5-membered heterocyclic ring, 6-membered heterocyclic ring, 7-membered heterocyclic ring, 5-membered carbocyclic, 6-membered carbocyclic, 7-membered carbocyclic or 8-membered carbocyclic; and each the ring systems contains 1, 2 or 3 heteroatoms select form N, O or S.
- ring is 5-membered heterocyclic ring containing 1, 2 or 3 heteroatoms select form N or O, 6-membered heterocyclic ring containing 1or 2 heteroatoms select form N or O or 5-membered carbocyclic.
- each R 32 and R 33 is independently -CH 2 NH 2 , -CH 2 NHBoc or methyl.
- Y 1 is N.
- Y 2 is C.
- R 4 is -NH 2 .
- the compound is of Formula III:
- X is absent or S
- R 26 is -H, halogen, substituted or unsubstituted C 1-3 alkyl, or substituted or unsubstituted C 1-3 alkoxy;
- ring is 5-8 member heteroaryl or 5-8 member heterocyclic ring; and each the ring system independently contains 1, 2, 3 or 4 heteroatoms select form N, O or S;
- n 0, 1, 2 or 3;
- R 4 is -H, halogen, -NH 2 , ubstituted or unsubstituted C 1-6 alkoxy, or substituted or unsubstituted C 1-6 alkyl;
- each R 35 and R 36 is independently -H, halogen, -OH, -NH 2 , -CN, -NO 2 , -CH 2 NH 2 , substituted or unsubstituted C 1-3 alkyl, or substituted or unsubstituted C 1-3 alkoxy;
- the present invention further provides some preferred technical solutions with regard to compound of Formula (III) .
- ring is 5-membered heteroaryl, 6-membered heteroaryl, 7-membered heteroaryl, 5-membered heterocyclic ring, 6-membered heterocyclic ring or 7-membered heterocyclic ring; and each of the ring system independently contains 1, 2 or 3 heteroatoms select form N, O or S.
- ring is 5-membered heterocyclic ring or 6-membered heterocyclic ring; and each of the ring system independently contains 1 or 2 heteroatoms select form N or O.
- R 26 is -H or -Cl
- R 4 is -NH 2 .
- each C 1-6 alkyl is independently methyl, ethyl, propyl, isopropyl, cyclopropyl, n-butyl, isobutyl, tert-buyl, n-pentyl, neopentyl, isopentyl, cyclopentyl, n-hexyl or cyclohexyl.
- each C 1-3 alkyl is independently methyl, ethyl, propyl, isopropyl or cyclopropyl.
- each C 1-3 alkoxy is independently methoxy, ethoxy, propoxy, isopropoxy or cyclopropyloxy.
- each C 2-3 alkylnyl is independently -C ⁇ CH, -CH 2 -C ⁇ CH, or -C ⁇ C-CH 3 .
- each halogen is independently -F, -Cl, -Br or -I.
- each heterocyclic group and each carbocyclic group includes single ring, spiral ring, bridge ring, fused ring and all various combinations of spiral ring, bridge ring, and/or fused ring.
- the said single ring includes the said spiral ring includes and the said various combinations of spiral ring, bridge ring, and/or fused ring include
- the present invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising at least one compound described herein and at least one pharmaceutically acceptable excipient.
- the said compound in a weight ratio to the said excipient within the range from about 0.0001 to about 10.
- the present invention additionally provided a use of the pharmaceutical composition of as described herein for the preparation of a medicament.
- a medicament thus prepared can be used for the treatment or prevention of cancer, cancer metastasis, cardiovascular disease, an immunological disorder or an ocular disorder.
- the present invention additionally provided a use of at least one compound described herein to prepare of a medicament.
- a medicament thus prepared can be used for the treatment or prevention of cancer, cancer metastasis, cardiovascular disease, an immunological disorder or an ocular disorder.
- At least one compound for use described herein which is for use in the treatment of cancer, the prevention of cancer metastasis or the treatment of cardiovascular disease, an immunological disorder or an ocular disorder.
- the condition mediated by the activity of SHP2 is cancer.
- the condition mediated by the activity of SHP2 is noonan syndrome, leopard syndrome, juvenile myelomonocytic leukemias, liver cancer, neuroblastoma, melanoma, squamous-cell carcinoma of the head and neck, acute myeloid leukemia, breast cancer, esophageal cancer, lung cancer, colon cancer, head cancer, gastric carcinoma, neuroblastoma, anaplastic large-cell lymphoma and glioblastoma.
- At least one compound described herein or a pharmaceutically acceptable salt thereof for use as a medicament At least one compound described herein or a pharmaceutically acceptable salt thereof for use as a medicament.
- At least one compound described herein or a pharmaceutically acceptable salt thereof for use in the treatment of cancer At least one compound described herein or a pharmaceutically acceptable salt thereof for use in the treatment of cancer.
- a method of treating cancer selected from the group consisting of noonan syndrome, leopard syndrome, juvenile myelomonocytic leukemias, liver cancer, neuroblastoma, melanoma, squamous-cell carcinoma of the head and neck, acute myeloid leukemia, breast cancer, esophageal cancer, lung cancer, colon cancer, head cancer, gastric carcinoma, neuroblastoma, anaplastic large-cell lymphoma and glioblastoma in a mammal comprising administering to a mammal in need of such treatment an effective amount of at least one compound described herein or a pharmaceutically acceptable salt thereof
- halogen means fluoro, chloro, bromo or iodo.
- the preferred halogen groups include F, Cl and Br.
- haloC 1-6 alkyl means fluoro, chloro, bromo or iodo.
- the preferred halogen groups include F, Cl and Br.
- haloC 1-6 alkyl means fluoro, chloro, bromo or iodo.
- the preferred halogen groups include F, Cl and Br.
- haloC 1-6 alkyl , “haloC 2-6 alkenyl” , “haloC 2-6 alkynyl” and “haloC 1-6 alkoxy” mean a C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl or C 1-6 alkoxy in which one or more (in particular, 1 to 3) hydrogen atoms have been replaced by halogen atoms, especially fluorine or chlorine atoms.
- fluoroC 1-6 alkyl, fluoroC 2-6 alkenyl, fluoroC 2-6 alkynyl and fluoroC 1-6 alkoxy groups in particular fluoroC 1-3 alkyl, for example, CF 3 , CHF 2 , CH 2 F, CH 2 CH 2 F, CH 2 CHF 2 , CH 2 CF 3 and fluoroC 1-3 alkoxy groups, for example, OCF 3 , OCHF 2 , OCH 2 F, OCH 2 CH 2 F, OCH 2 CHF 2 or OCH 2 CF 3 , and most especially CF 3 , OCF 3 and OCHF 2 .
- fluoroC 1-3 alkyl for example, CF 3 , CHF 2 , CH 2 F, CH 2 CH 2 F, CH 2 CHF 2 , CH 2 CF 3 and fluoroC 1-3 alkoxy groups, for example, OCF 3 , OCHF 2 , OCH 2 F, OCH 2 CH 2 F, OCH 2 CHF 2 or OCH
- alkyl includes saturated monovalent hydrocarbon radicals having straight, branched or cyclic moieties.
- alkyl radicals include methyl, ethyl, propyl, isopropyl, cyclcopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, cyclcobutyl, n-pentyl, 3- (2-methyl) butyl, 2-pentyl, 2-methylbutyl, neopentyl, cyclcopentyl, n-hexyl, 2-hexyl, 2-methylpentyl and cyclohexyl.
- C 1-8 as in C 1-8 alkyl is defined to identify the group as having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms in a linear or branched arrangement.
- Alkylene means a difunctional group obtained by removal of a hydrogen atom from an alkyl group that is defined above.
- methylene i.e., -CH 2 -
- ethylene i.e., -CH 2 -CH 2 - or –CH (CH 3 ) -
- propylene i.e., -CH 2 -CH 2 -CH 2 -, -CH (-CH 2 -CH 3 ) -or –CH 2 -CH (CH 3 ) -
- Alkenyl and alkynyl groups include straight, branched chain or cyclic alkenes and alkynes.
- C 2-8 alkenyl and “C 2-8 alkynyl” means an alkenyl or alkynyl radicals having 2, 3, 4, 5, 6, 7 or 8 carbon atoms in a linear or brached arrangement.
- Alkoxy radicals are oxygen ethers formed from the previously described straight, branched chain or cyclic alkyl groups.
- aryl refers to an unsubstituted or substituted mono-or polycyclic ring system containing carbon ring atoms.
- the preferred aryls are mono cyclic or bicyclic 6-10 membered aromatic ring systems. Phenyl and naphthyl are preferred aryls. The most preferred aryl is phenyl.
- heterocyclic refers to unsubstituted and substituted mono-or polycyclic non-aromatic ring system containing one or more heteroatoms.
- Preferred heteroatoms include N, O, and S, including N-oxides, sulfur oxides, and dioxides.
- the ring is three to eight membered and is either fully saturated or has one or more degrees of unsaturation. Multiple degrees of substitution, preferably one, two or three, are included within the present definition.
- heterocyclic groups include, but are not limited to azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, oxopiperazinyl, oxopiperidinyl, oxoazepinyl, azepinyl, tetrahydrofuranyl, dioxolanyl, tetrahydroimidazolyl, tetrahydrothiazolyl, tetrahydrooxazolyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl, thiamorpholinyl sulfoxide, thiamorpholinyl sulfone and oxadiazolyl.
- heteroaryl represents an aromatic ring system containing carbon (s) and at least one heteroatom.
- Heteroaryl may be monocyclic or polycyclic, substituted or unsubstituted.
- a monocyclic heteroaryl group may have 1 to 4 heteroatoms in the ring, while a polycyclic heteroaryl may contain 1 to 10 hetero atoms.
- a polycyclic heteroaryl ring may contain fused, spiro or bridged ring junction, for example, bycyclic heteroaryl is a polycyclic heteroaryl.
- Bicyclic heteroaryl rings may contain from 8 to 12 member atoms.
- Monocyclic heteroaryl rings may contain from 5 to 8 member atoms (cabons and heteroatoms) .
- heteroaryl groups include, but are not limited to thienyl, furanyl, imidazolyl, isoxazolyl, oxazolyl, pyrazolyl, pyrrolyl, thiazolyl, thiadiazolyl, triazolyl, pyridyl, pyridazinyl, indolyl, azaindolyl, indazolyl, benzimidazolyl, benzofuranyl, benzothienyl, benzisoxazolyl, benzoxazolyl, benzopyrazolyl, benzothiazolyl, benzothiadiazolyl, benzotriazolyl adeninyl, quinolinyl or isoquinolinyl.
- cycloalkyl refers to a substituted or unsubstituted monocyclic, bicyclic or polycyclic non-aromatic saturated ring, which optionally includes an alkylene linker through which the cycloalkyl may be attached.
- Examplary "cycloalkyl” groups includes but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and so on.
- alkyl or aryl or either of their prefix roots appear in a name of a substituent (e.g., aralky or dialkylamino) it shall be interpreted as including those limitations given above for “alkyl” and “aryl. " Designated numbers of carbon atoms (e.g., C l-6 ) shall refer independently to the number of carbon atoms in an alkyl moiety or to the alkyl portion of a larger substituent in which alkyl appears as its prefix root.
- composition is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combinations of the specified ingredients in the specified amounts. Accordingly, pharmaceutical compositions containing the compounds of the present invention as the active ingredient as well as methods of preparing the instant compounds are also part of the present invention. Furthermore, some of the crystalline forms for the compounds may exist as polymorphs and as such are intended to be included in the present invention. In addition, some of the compounds may form solvates with water (i.e., hydrates) or common organic solvents and such solvates are also intended to be encompassed within the scope of this invention.
- the compounds of the present invention may also be present in the form of pharmaceutically acceptable salts.
- the salts of the compounds of this invention refer to non-toxic "pharmaceutically acceptable salts" .
- the pharmaceutically acceptable salt forms include pharmaceutically acceptable acidic/anionic or basic/cationic salts.
- the pharmaceutically acceptable acidic/anionic salt generally takes a form in which the basic nitrogen is protonated with an inorganic or organic acid.
- organic or inorganic acids include hydrochloric, hydrobromic, hydriodic, perchloric, sulfuric, nitric, phosphoric, acetic, propionic, glycolic, lactic, succinic, maleic, fumaric, malic, tartaric, citric, benzoic, mandelic, methanesulfonic, hydroxyethanesulfonic, benzenesulfonic, oxalic, pamoic, 2-naphthalenesulfonic, p-toluenesulfonic, cyclohexanesulfamic, salicylic, saccharinic or trifluoroacetic.
- Pharmaceutically acceptable basic/cationic salts include, and are not limited to aluminum, calcium, chloroprocaine, choline, diethanolamine, ethylenediamine, lithium, magnesium, potassium, sodium and zinc.
- the present invention includes within its scope the prodrugs of the compounds of this invention.
- such prodrugs will be functional derivatives of the compounds that are readily converted in vivo into the required compound.
- the term “administering” shall encompass the treatment of the various disorders described with the compound specifically disclosed or with a compound which may not be specifically disclosed, but which converts to the specified compound in vivo after administration to the subject.
- Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs” , ed. H. Bundgaard, Elsevier, 1985.
- the present invention includes compounds described can contain one or more asymmetric centers and may thus give rise to diastereomers and optical isomers.
- the present invention includes all such possible diastereomers as well as their racemic mixtures, their substantially pure resolved enantiomers, all possible geometric isomers, and pharmaceutically acceptable salts thereof.
- the above Formula I is shown without a definitive stereochemistry at certain positions.
- the present invention includes all stereoisomers of Formula I and pharmaceutically acceptable salts thereof. Further, mixtures of stereoisomers as well as isolated specific stereoisomers are also included. During the course of the synthetic procedures used to prepare such compounds, or in using racemization or epimerization procedures known to those skilled in the art, the products of such procedures can be a mixture of stereoisomers.
- the present invention includes any possible tautomers and pharmaceutically acceptable salts thereof, and mixtures thereof, except where specifically stated otherwise.
- the present invention includes any possible solvates and polymorphic forms.
- a type of a solvent that forms the solvate is not particularly limited so long as the solvent is pharmacologically acceptable.
- water, ethanol, propanol, acetone or the like can be used.
- pharmaceutically acceptable salts refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids.
- the compound of the present invention is acidic, its corresponding salt can be conveniently prepared from pharmaceutically acceptable non-toxic bases, including inorganic bases and organic bases.
- the compound of the present invention is basic, its corresponding salt can be conveniently prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids. Since the compounds of Formula (I) are intended for pharmaceutical use they are preferably provided in substantially pure form, for example at least 60%pure, more suitably at least 75%pure, especially at least 98%pure (%are on a weight for weight basis) .
- compositions of the present invention comprise a compound represented by Formula I (or a pharmaceutically acceptable salt thereof) as an active ingredient, a pharmaceutically acceptable carrier and optionally other therapeutic ingredients or adjuvants.
- the compositions include compositions suitable for oral, rectal, topical, and parenteral (including subcutaneous, intramuscular, and intravenous) administration, although the most suitable route in any given case will depend on the particular host, and nature and severity of the conditions for which the active ingredient is being administered.
- the pharmaceutical compositions may be conveniently presented in unit dosage form and prepared by any of the methods well known in the art of pharmacy.
- the compounds represented by Formula I, or a prodrug, or a metabolite, or pharmaceutically acceptable salts thereof, of this invention can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques.
- the carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., oral or parenteral (including intravenous) .
- the pharmaceutical compositions of the present invention can be presented as discrete units suitable for oral administration such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient.
- compositions can be presented as a powder, as granules, as a solution, as a suspension in an aqueous liquid, as a non-aqueous liquid, as an oil-in-water emulsion, or as a water-in-oil liquid emulsion.
- the compound represented by Formula I, or a pharmaceutically acceptable salt thereof may also be administered by controlled release means and/or delivery devices.
- the compositions may be prepared by any of the methods of pharmacy. In general, such methods include a step of bringing into association the active ingredient with the carrier that constitutes one or more necessary ingredients.
- the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both. The product can then be conveniently shaped into the desired presentation.
- compositions of this invention may include a pharmaceutically acceptable carrier and a compound, or a pharmaceutically acceptable salt, of Formula I.
- the compounds of Formula I, or pharmaceutically acceptable salts thereof, can also be included in pharmaceutical compositions in combination with one or more other therapeutically active compounds.
- the pharmaceutical carrier employed can be, for example, a solid, liquid, or gas.
- solid carriers include lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, and stearic acid.
- liquid carriers are sugar syrup, peanut oil, olive oil, and water.
- gaseous carriers include carbon dioxide and nitrogen.
- oral liquid preparations such as suspensions, elixirs and solutions
- carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like may be used to form oral solid preparations such as powders, capsules and tablets.
- oral solid preparations such as powders, capsules and tablets.
- tablets and capsules are the preferred oral dosage units whereby solid pharmaceutical carriers are employed.
- tablets may be coated by standard aqueous or nonaqueous techniques.
- a tablet containing the composition of this invention may be prepared by compression or molding, optionally with one or more accessory ingredients or adjuvants.
- Compressed tablets may be prepared by compressing, in a suitable machine, the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent.
- Each tablet preferably contains from about 0.05mg to about 5g of the active ingredient and each cachet or capsule preferably containing from about 0.05mg to about 5g of the active ingredient.
- a formulation intended for the oral administration to humans may contain from about 0.5mg to about 5g of active agent, compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95 percent of the total composition.
- Unit dosage forms will generally contain between from about lmg to about 2g of the active ingredient, typically 25mg, 50mg, l00mg, 200mg, 300mg, 400mg, 500mg, 600mg, 800mg, or l000mg.
- compositions of the present invention suitable for parenteral administration may be prepared as solutions or suspensions of the active compounds in water.
- a suitable surfactant can be included such as, for example, hydroxypropylcellulose.
- Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils. Further, a preservative can be included to prevent the detrimental growth of microorganisms.
- compositions of the present invention suitable for injectable use include sterile aqueous solutions or dispersions.
- the compositions can be in the form of sterile powders for the extemporaneous preparation of such sterile injectable solutions or dispersions.
- the final injectable form must be sterile and must be effectively fluid for easy syringability.
- the pharmaceutical compositions must be stable under the conditions of manufacture and storage; thus, preferably should be preserved against the contaminating action of microorganisms such as bacteria and fungi.
- the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol) , vegetable oils, and suitable mixtures thereof.
- compositions of the present invention can be in a form suitable for topical use such as, for example, an aerosol, cream, ointment, lotion, dusting powder, or the like. Further, the compositions can be in a form suitable for use in transdermal devices. These formulations may be prepared, utilizing a compound represented by Formula I of this invention, or a pharmaceutically acceptable salt thereof, via conventional processing methods. As an example, a cream or ointment is prepared by admixing hydrophilic material and water, together with about 5wt%to about 10wt%of the compound, to produce a cream or ointment having a desired consistency.
- compositions of this invention can be in a form suitable for rectal administration wherein the carrier is a solid. It is preferable that the mixture forms unit dose suppositories. Suitable carriers include cocoa butter and other materials commonly used in the art. The suppositories may be conveniently formed by first admixing the composition with the softened or melted carrier (s) followed by chilling and shaping in molds.
- the pharmaceutical formulations described above may include, as appropriate, one or more additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including antioxidants) and the like.
- additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including antioxidants) and the like.
- additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including antioxidants) and the like.
- additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including antioxidants) and the like.
- other adjuvants can be included to render the formulation isotonic with the blood of the intended recipient.
- dosage levels on the order of from about 0.01mg/kg to about 150mg/kg of body weight per day are useful in the treatment of the above-indicated conditions, or alternatively about 0.5mg to about 7g per patient per day.
- inflammation, cancer, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system (CNS) may be effectively treated by the administration of from about 0.01 to 50mg of the compound per kilogram of body weight per day, or alternatively about 0.5mg to about 3.5g per patient per day.
- DIEA N, N-Diisopropylethylamine
- DMSO Dimethyl sulfoxide
- EA Ethyl acetate
- NMP N-methyl-2-pyrrolidone
- TEA Triethylamine
- TFA Trifluoroacetic acid
- Xantphos Dimethylbisdiphenylphosphinoxanthene
- Pre-TLC Preparation by thin layer chromatogaraphy.
- Oxalyl chloride was added dropwise to a solution of2- (dimethylamino) -2-oxoacetic acid (0.26 g, 2.15 mmol) in DCM (10mL) , and stirred at RT for 2 hours, the volatiles were removed under reduced pressure, the residue was dissloved in DCM (10mL) and added dropwise to a solution of the compound 1e (0.55g, 1.08mmol) in DCM (10mL) , after completion of the reaction, the reaction mixture was quenched by addition of ice-water (20mL) , washed with brine, dried over anhydrous Na 2 SO 4 , filtered and the volatiles were removed under reduced pressure and purified by column chromatography to afford the compound 1f (0.42g, 64%) . MS: 610 (M+H) + .
- Chloral hydrate (50.02g) and Na 2 SO 4 (350.21g) were dissolved in water (700mL) in a 3 L beaker and warmed to 35°C.
- a warm solution of the appropriate commercial aniline derivative (60.45g, 0.276mol) in water (200mL) was added (awhite precipitate of the amine sulfate was formed) , followed by a warm solution of hydroxylamine hydrochloride (61.18g, 0.88mol) in water (275mL) .
- Example SHP2 inhibition (%) Example SHP2 inhibition (%) 3@0.1 ⁇ M 60 7@0.1 ⁇ M 79 8@0.1 ⁇ M 76 10@0.1 ⁇ M 81 20@0.1 ⁇ M 57 29@0.1 ⁇ M 47 31@0.1 ⁇ M 53 32@0.1 ⁇ M 49 34@0.1 ⁇ M 37 35@0.1 ⁇ M 30 38@0.1 ⁇ M 30 40@0.1 ⁇ M 71 42@0.1 ⁇ M 58 43@0.1 ⁇ M 43 58@0.1 ⁇ M 61 72@0.1 ⁇ M 31 74@0.1 ⁇ M 75 75@0.1 ⁇ M 35
- IC 50 values were estimated using 6, 8-difluoro-4-methylumbelliferyl phosphate (DiFMUP) as a substrate, SHP2 samples (diluted to 0.5 nM in reaction buffer) were incubated with dPEG8 peptide for 30 min in reaction buffer [60 mM 3, 3-dimethyl glutarate (pH7.2) , 75 mM NaCl, 75 mM KCl, and 1 mM EDTA, 0.05%Tween 20, 2mM dithiothreitol (DTT) ] to active the PTP.
- reaction buffer 60 mM 3, 3-dimethyl glutarate (pH7.2) , 75 mM NaCl, 75 mM KCl, and 1 mM EDTA, 0.05%Tween 20, 2mM dithiothreitol (DTT)
- DMSO [0.5% (v/v) ] or compounds (concentrations ranging from 0.3 nM to 1 ⁇ M) were added to the mixture and incubated for 30 min at room temperature. Reactions were initiated by the addition of DiFMUP (12 ⁇ M; total reaction volume of 100 ⁇ L) , and the fluorescence (excitation at 340 nm, emission at 450 nm) of the resulting solutions was measured on a 2104-0020 EnVision Xcite Multilabel Reader (PerkinElmer) after 30min. The IC 50 results of the compounds of the invention were shown by table 2.
- Example IC 50 (nM) Example IC 50 (nM) 7@ 25.8 8@ 21.4 10@ 30 40@ 40.6 74@ 8.3 SHP099 84
- KYSE-520 (1500 cells/well) were plated onto 96-well plates in 100 ⁇ L medium (RPMI-1640 containing 3%FBS for KYSE-520 cells, Gibco) .
- compounds of the invention at various concentrations were added 24 hours after cell plating.
- 50 ⁇ L MTS/PMS reagents (Promega/Sigma) were added, and the absorbance value was determined according to the supplier's instruction (Promega) .
- the IC 50 results of the compounds of the invention were shown by table 3.
- Example IC 50 ( ( ⁇ M) Example IC 50 ( ( ⁇ M) 1 15.94 7 2.17 8 26.38 11 12.04 13 20.57 74 3.38
- the compounds of the present invention are preferably formulated as pharmaceutical compositions administered by a variety of routes. Most preferably, such compositions are for oral administration. Such pharmaceutical compositions and processes for preparing the same are well known in the art. See, e.g., REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY (A. Gennaro, et al, eds., 19 th ed., Mack Publishing Co., 1995) .
- the compounds of Formula I are generally effective over a wide dosage range.
- dosages per day normally fall within the range of about 1 mg to about 200 mg total daily dose, preferably 1 mg to 150 mg total daily dose, more preferably 1 mg to 50 mg total daily dose. In some instances dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed.
- the above dosage range is not intended to limit the scope of the invention in any way. It will be understood that the amount of the compound actually administered will be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound or compounds administered, the age, weight, and response of the individual patient, and the severity of the patient's symptoms.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Description
Example | SHP2 inhibition (%) | Example | SHP2 inhibition (%) |
3@0.1μM | 60 | 7@0.1μM | 79 |
8@0.1μM | 76 | 10@0.1μM | 81 |
20@0.1μM | 57 | 29@0.1μM | 47 |
31@0.1μM | 53 | 32@0.1μM | 49 |
34@0.1μM | 37 | 35@0.1μM | 30 |
38@0.1μM | 30 | 40@0.1μM | 71 |
42@0.1μM | 58 | 43@0.1μM | 43 |
58@0.1μM | 61 | 72@0.1μM | 31 |
74@0.1μM | 75 | 75@0.1μM | 35 |
Example | IC50 (nM) | Example | IC50 (nM) |
7@ | 25.8 | 8@ | 21.4 |
10@ | 30 | 40@ | 40.6 |
74@ | 8.3 | SHP099 | 84 |
Example | IC50 ( (μM) | Example | IC50 ( (μM) |
1 | 15.94 | 7 | 2.17 |
8 | 26.38 | 11 | 12.04 |
13 | 20.57 | 74 | 3.38 |
Claims (85)
- A compound of Formula I or a pharmaceutically acceptable salt:X is absent, O, S, SO, S (O) 2, C (O) , C (O) R11, CR11R12, or -NR11; and each R11 and R12 is independently -H, halogen, -NH2, -CN, -OH, -NO2, carbonyl, =O, oxo, carboxyl, substituted or unsubstituted C1-6alkoxy, or substituted or unsubstituted C1-6alkyl;Y1 is N or CR1;Y2 is N or CR2;each R1 and R2 is independently -H, halogen, -CN, -OH, -NH2, -N3, -NO2, substituted or unsubstituted C1-6alkoxy, or substituted or unsubstituted C1-6alkyl; orR1 combines with R3, or R2 combines with R3, to form a 5-10 member heteroaryl, 5-10 member carbocyclic or 5-10 member heterocyclic ring, wherein each of the ring systems is independently optionally substituted with halogen, -CN, -OH, -NR8R9, -N3, -NO2, carbonyl, =O, oxo, substituted or unsubstituted C1-6alkyl, substituted or unsubstituted C1-6alkoxy, or C (O) R8; orR3 is -H, halogen, -CN, -OH, -N3, -NO2, -NR8R9, -N (R8) (CH2) pNR8R9, -N (R8) (CH2) pR8, -N (R8) GpR8, -N (R8) GpNR8R9, -N (R8) (C=O) qR8, -N (R8) (C=O) qNR8R9, -N (R8) (C=O) qGpR8, -N (R8) (C=O) qGpNR8R9, -N (R8) (C=O) qGp (C=O) qR8, -N (R8) (C=O) qGp (C=O) qNR8R9, -N (R8) (C=O) qN (R8) (C=O) qR8, -N (R8) (C=O) qN (R8) (C=O) qNR8R9, -N (R8) (C=O) qN (R8) Gq (C=O) pR8, -N (R8) (C=O) qN (R8) Gp (C=O) qNR8R9, C (O) qR8, C (O) OR8, C (O) NH2, C (O) NHR8, C (O) NR8R9, C1-6alkyl, C6-10aryl, arylalkyl, alkoxy, heteroaryl, heterocyclic, or carbocyclic; and each of which may be optionally substituted; and each p and q is independently 0, 1, 2 or 3;each G is independently C6-10ary, C3-8carbocyclic or C5-10heteroaryl; and each of which may be optionally substituted;R4 is -H, halogen, -CN, -OH, -NR8R9, -N3, -NO2, substituted or unsubstituted C1-6alkoxy, substituted or unsubstituted C1-6alkyl, C5-18heterocyclic or C5-18carbocyclic; wherein each of the ring systems is independently optionally substituted with halogen, -CN, -OH, -NO2, carbonyl, =O, oxo, substituted or unsubstituted C1-6alkyl, substituted or unsubstituted C1-6alkoxy, -NR8R9 or -CH2NR8R9;R5 is -H, halogen, -CN, -OH, -NR8R9, -N3, -NO2, C1-6alkyl, C1-6alkoxy, C6-10aryl, C6-10arylalkyl, C6-10heteroaryl, C5-18heterocyclic or C5-18carbocyclic; and each of which is independently optionally substituted;each R8 and R9 is independently -H, halogen, -CN, -OH, -N3, -NO2, C1-6alkyl, C1-6alkoxy, C2-6alkenyl, NH (C1-6alkyl) , N (C1-6alkyl) 2, C5-10heterocyclicor C5-10carbocyclic; and each of which may be independently optionally substituted.
- The compound of claim 1, wherein R1 is -H, -F, -Cl, -Br, -I, -CN, -OH, -NH2, substituted or unsubstituted C1-3alkoxy, or substituted or unsubstituted C1-3alkyl.
- The compound of claim 1 or 2, wherein R1 is -H, -F, -Cl, -NH2, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy; and each methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy is independently optionally substituted with halogen, OH or NH2.
- The compound of any one of claims 1-3, wherein R2 is -H, -F, -Cl, -Br, -I, -CN, -OH, -NH2, substituted or unsubstituted C1-3alkoxy, or substituted or unsubstituted C1-3alkyl.
- The compound ofany one of claims 1-4, wherein R2 is -H, -F, -Cl, -NH2, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy; and each methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy is independently optionally substituted with halogen, OH or NH2.
- The compound of any one of claims 1-5, wherein R3 is -H, -F, -Cl, -Br, -CN, -OH, -NO2, -NR8R9, -N (R8) (CH2) pNR8R9, -N (R8) (CH2) pR8, -N (R8) GpR8, -N (R8) GpNR8R9, -N (R8) (C=O) qR8, -N (R8) (C=O) qNR8R9, -N (R8) (C=O) qGpR8, -N (R8) (C=O) qGpNR8R9, -N (R8) (C=O) qGp (C=O) qR8, -N (R8) (C=O) qGp (C=O) qNR8R9, -N (R8) (C=O) qN (R8) (C=O) qR8, -N (R8) (C=O) qN (R8) (C=O) qNR8R9, -N (R8) (C=O) qN (R8) Gq (C=O) pR8, -N (R8) (C=O) qN (R8) Gp (C=O) qNR8R9, C (O) qR8, C (O) OR8, C (O) NH2, C (O) NHR8, C (O) NR8R9, C1-6alkyl or C6-10aryl; and each of which may be optionally substituted with halogen, -CN, -OH, -NH2, -N3, -NO2, substituted or unsubstituted C1-6alkyl, or substituted or unsubstituted C1-6alkoxy.
- The compound of any one of claims 1-6, wherein R3 is -H, -F, -Cl, -Br, -NR8R9, -N (R8) (CH2) pNR8R9, -N (R8) (CH2) pR8, -N (R8) GpR8, -N (R8) GpNR8R9, -N (R8) (C=O) qR8, -N (R8) (C=O) qNR8R9, -N (R8) (C=O) qGpR8, -N (R8) (C=O) qGpNR8R9, -N (R8) (C=O) qGp (C=O) qR8, -N (R8) (C=O) qGp (C=O) qNR8R9, -N (R8) (C=O) qN (R8) (C=O) qR8, -N (R8) (C=O) qN (R8) (C=O) qNR8R9, -N (R8) (C=O) qN (R8) Gq (C=O) pR8, -N (R8) (C=O) qN (R8) Gp (C=O) qNR8R9orC (O) qR8, and each of which may be optionally substituted with -F, -Cl, -Br, -I, -CN, -OH, -NH2, -N3, -NO2, substituted or unsubstituted C1-3alkyl, or substituted or unsubstituted C1-3alkoxy.
- The compound of any one of claims 1-7, wherein R3 is -H, -NR8R9, -N (R8) (C=O) qR8, -N (R8) (C=O) qNR8R9, -N (R8) (C=O) qGpR8, -N (R8) (C=O) qGp (C=O) qNR8R9, -N (R8) (C=O) qN (R8) Gp (C=O) qNR8R9 orC (O) qR8; and each of which may be optionally substituted with -F, -Cl, -Br, -NHmethyl, -NHethyl, -NHpropyl, -NHisopropyl, -NHOCH3, -NHOCH2CH3, -NHCH2OCH3, -NHOCH2CH2CH3, -NHCH2OCH2CH3, -NHCH2CH2OCH3, -NHOCH (CH3) 2, -NHCH (OCH3) 2, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy; and each methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy is independently optionally substituted with -F, -Cl, -Br or -I.
- The compound of any one of claims 1-8, wherein each G is independently 6-membered aryl, 7-membered aryl, 8-membered aryl, 3-membered carbocyclic, 4-membered carbocyclic, 5-membered carbocyclic, 6-membered carbocyclic or 7-membered carbocyclic; and each of which may be optionally substituted with halogen, -CN, -OH, -NH2, -N3, -NO2, substituted or unsubstituted C1-6alkyl, or substituted or unsubstituted C1-6alkoxy.
- The compound of any one of claims 1-9, wherein each G is independently 6-membered aryl, 7-membered aryl, 8-membered aryl, 3-membered carbocyclic, 4-membered carbocyclic, 5-membered carbocyclic or 6-membered carbocyclic; and each of which may be optionally substituted with -F, -Cl, -Br, -CN, -OH, -NH2, -NO2, substituted or unsubstituted C1-3alkyl, or substituted or unsubstituted C1-3alkoxy.
- The compound of any one of claims 1-10, wherein each G is independently phenyl, and which may be optionally substituted with -F, -Cl, -OH, -NH2, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy; and each methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy is independently optionally substituted with -F, -Cl, -Br or -I.
- The compound of any one of claims 1-11, wherein each G is independently 5-membered heteroaryl, 6-membered heteroaryl, 7-membered heteroaryl or 8-membered heteroaryl; and each of which contains 1, 2, 3 or 4 heteroatoms select from N, O or S, and may be optionally substituted with halogen, -CN, -OH, -NH2, -N3, -NO2, substituted or unsubstituted C1-6alkyl, or substituted or unsubstituted C1-6alkoxy.
- The compound of any one of claims 1-12, wherein p is 0 or 1.
- The compound of any one of claims 1-13, wherein q is 1 or 2.
- The compound of any one of claims 1-15, wherein R1 is combines with R3, orR2 is combines with R3, to form a 5-10 member heteroaryl or 5-10 member heterocyclic ring, wherein each of the ring systems is optionally substituted with halogen, -CN, -OH, -NH2, carbonyl, =O, oxo, substituted or unsubstituted C1-6alkyl, substituted or unsubstituted C1-6alkoxy, or C (O) R8.
- The compound of any one of claims 1-16, wherein R1 is combines with R3, or R2 is combines with R3, to form a 5-membered heteroaryl, 6-membered heteroaryl, 7-membered heteroaryl, 8-membered heteroaryl, 5-membered heterocyclic ring, 6-membered heterocyclic ring, 7-membered heterocyclic ring or 8-membered heterocyclic ring; wherein each of the ring systems contains 1, 2, 3 or 4 heteroatoms select from N, O or S, and is optionally substituted with -F, -Cl, -Br, -I, -CN, -OH, -NH2, carbonyl, =O, oxo, substituted or unsubstituted C1-3alkyl, substituted or unsubstituted C1-3alkoxy or C (O) R8.
- The compound of any one of claims 1-17, wherein R1 is combines with R3 to form a 5-10 member heteroaryl or a 5-10 member heterocyclic ring; wherein each of the ring systems is optionally substituted with halogen, -CN, -OH, -NH2, carbonyl, =O, oxo, substituted or unsubstituted C1-6alkyl, substituted or unsubstituted C1-6alkoxy or C (O) R8.
- The compound of any one of claims 1-18, wherein R1 is combines with R3 to form a 5-membered heteroaryl, 6-membered heteroaryl, 7-membered heteroaryl, 8-membered heteroaryl, 5-membered heterocyclic ring, 6-membered heterocyclic ring, 7-membered heterocyclic ring or 8-membered heterocyclic ring, wherein each of the ring systems contains 1, 2, 3 or 4 heteroatoms select from N, O or S, and is optionally substituted with -F, -Cl, -Br, -I, -CN, -OH, -NH2, carbonyl, =O, oxo, substituted or unsubstituted C1-3alkyl, substituted or unsubstituted C1-3alkoxy or C (O) R8.
- The compound of any one of claims 1-19, wherein R1 is combines with R3 to form a 5-membered heteroaryl, 6-membered heteroaryl, 5-membered heterocyclic ring or 6-membered heterocyclic ring, wherein each of the ring systems contains 1 or 2 heteroatoms select from N or O, and is optionally substituted with -F, -Cl, -Br, -OH, -NH2, -NHmethyl, -NHethyl, -NHpropyl, -NHisopropyl, -NHOCH3, carbonyl, =O, oxo, methyl, ethyl, propyl, isopropyl, methoxy, CHF2, CH2F, CF3 or C (O) R8; and each methyl, ethyl, propyl, isopropyl, methoxy, CHF2, CH2F or C (O) R8 is independently optionally substituted with -F, -Cl, -Br or -I.
- The compound of any one of claims 1-17, wherein R2 is combines with R3 to form a 5-10 member heteroaryl or 5-10 member heterocyclic ring, wherein each of the ring systems is optionally substituted with halogen, -CN, -OH, -NH2, carbonyl, =O, oxo, substituted or unsubstituted C1-6alkyl, substituted or unsubstituted C1-6alkoxy or C (O) R8.
- The compound of any one of claims 1-17 or 21, wherein R2 is combines with R3 to form a 5-membered heteroaryl, 6-membered heteroaryl, 7-membered heteroaryl, 8-membered heteroaryl, 5-membered heterocyclic ring, 6-membered heterocyclic ring, 7-membered heterocyclic ring or 8-membered heterocyclic ring, wherein each of the ring systems contains 1, 2, 3 or 4 heteroatoms select from N, O or S, and is optionally substituted with -F, -Cl, -Br, -I, -CN, -OH, -NH2, carbonyl, =O, oxo, substituted or unsubstituted C1-3alkyl, substituted or unsubstituted C1-3alkoxy or C (O) R8.
- The compound of any one of claims 1-22, wherein R4 is -H, -F, -Cl, -Br, -CN, -OH, -NR8R9, substituted or unsubstituted C1-6alkyl, substituted or unsubstituted C1-6alkoxy, C5-18heterocyclic or C5-10carbocyclic, wherein each of the ring systems is optionally substituted with -F, -Cl, -Br, -CN, -OH, -NO2, carbonyl, =O, oxo, substituted or unsubstituted C1-6alkyl, substituted or unsubstituted C1-6alkoxy, -NH2, -NH-C1-6alkyl, -NH-C1-6alkoxy, -C1-6alkylene-NH2 or -C1-6alkylene-NH-C1-6alkyl.
- The compound of any one of claims 1-23, wherein R4 is H, -F, -Cl, -CN, -OH, -NH2, substituted or unsubstituted C1-3alkyl, substituted or unsubstituted C1-3alkoxy, 5-membered heterocyclic containing 1, 2 or 3 heteroatoms select from N or O, 6-membered heterocyclic containing 1, 2 or 3 heteroatoms select from N or O, 5-membered carbocyclic or 6-membered carbocyclic; wherein each of the ring systems is optionally substituted with -F, -Cl, -Br, -CN, -OH, carbonyl, =O, oxo, substituted or unsubstituted C1-3alkyl, substituted or unsubstituted C1-3alkoxy, -NH2, -NH-C1-3alkyl, -NH-C1-3alkoxy, -C1-3alkylene-NH2 or -C1-3alkylene-NH-C1-3alkyl.
- The compound of any one of claims 1-24, wherein R4 is -Cl, -NH2, methyl or piperidinyl, wherein the ring system is optionally substituted with methyl, -NH2 or -CH2NH2.
- The compound of any one of claims 1-25, wherein R5 is -H, -F, -Cl, -Br, -I, -NR8R9, C1-3alkyl, C1-3alkoxy, C6-9aryl, C6-9arylalkyl, C6-9heteroaryl, C6-17heterocyclic or C6-17carbocyclic, wherein each of which is independently optionally substituted with halogen, -CN, -OH, -N3, -NO2, -NH2, carbonyl, =O, oxo, substituted or unsubstituted C1-6alkyl, substituted or unsubstituted C1-6alkoxy, substituted or unsubstituted (CH2) kNR8R9, substituted or unsubstituted (CH2) kNHC (O) OR8 or C (O) R8; and k is 0, 1 or 2.
- The compound of claim 26, wherein the C6-9heteroaryl contains 1, 2, 3 or 4 heteroatoms select from N, O or S, and the C6-9heteroaryl is 6-membered heteroaryl, 7-membered heteroaryl, 8-membered heteroaryl or 9-membered heteroaryl; the C6-17heterocyclic contains 1, 2, 3, 4, 5, or 6 heteroatoms select from N, O, or S, and the C6-17heterocyclic is 6-membered heterocyclic, 7-membered heterocyclic, 8-membered heterocyclic, 9-membered heterocyclic, 10-membered heterocyclic, 11-membered heterocyclic, 12-membered heterocyclic, 13-membered heterocyclic, 14-membered heterocyclic, 15-membered heterocyclic, 16-membered heterocyclic or 17-membered heterocyclic.
- The compound of any one of claims 1-27, wherein R5 is -F, -Cl, -Br, -NR8R9, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, 6-membered aryl, 7-membered aryl, 8-membered aryl, 9-membered aryl, 6-membered arylalkyl, 7-membered arylalkyl, 8-membered arylalkyl, 9-membered arylalkyl, 6-membered heteroaryl, 7-membered heteroaryl, 8-membered heteroaryl, 9-membered heteroaryl, 6-membered heterocyclic, 7-membered heterocyclic, 8-membered heterocyclic, 9-membered heterocyclic, 10-membered heterocyclic, 11-membered heterocyclic, 12-membered heterocyclic, 13-membered heterocyclic, 14-membered heterocyclic, 15-membered heterocyclic, 16-membered heterocyclic, 6-membered carbocyclic, 7-membered carbocyclic, 8-membered carbocyclic, 9-membered carbocyclic, 10-membered carbocyclic, 11-membered carbocyclic, 12-membered carbocyclic, 13-membered carbocyclic, 14-membered carbocyclic, 15-membered carbocyclic or 16-membered carbocyclic; and each heteroaryl contains 1, 2 or 3 heteroatoms select from N, O or S, and each heterocyclic contains 1, 2, 3, or 4 heteroatoms select from N, O or S; wherein each of which is independently optionally substituted with -F, -Cl, -Br, -I, -CN, -OH, -NO2, -NH2, carbonyl, =O, oxo, substituted or unsubstituted C1-3alkyl, substituted or unsubstituted C1-3alkoxy, substituted or unsubstituted (CH2) kNR8R9, substituted or unsubstituted (CH2) kNHC (O) OR8, or substituted or unsubstituted C (O) R8; and k is 0, 1 or 2.
- The compound of any one of claims 1-28, wherein:each R21 and R22 is independently halogen, C1-3alkyl, -NH2, -C1-3alkylene-NH2, -C1-3alkylene-NH-C1-3alkyl, -C1-3alkylene-N (C1-3alkyl) 2, -NHBoc or -CH2NHBoc;or R21 and R22 together with the carbon atom to which they are both attached form a 5-10 member heteroaryl, 5-10 member carbocyclic or a 5-10 member heterocyclic ring, wherein each of the ring system is optionally substituted withhalogen, -CN, -OH, carbonyl, =O, oxo, -C1-3alkylene-NH2,-C1-3alkylene-NH-C1-3alkyl, -C1-3alkylene-N (C1-3alkyl) 2, -NHBoc, -CH2NHBoc;-NH2, C1-3alkoxy or C1-3alkyl.
- The compound of claim 29, wherein, R21 and R22 together with the carbon atom to which they are both attached form a 5-membered heteroaryl, 6-membered heteroaryl, 7-membered heteroaryl, 8-membered heteroaryl, 9-membered heteroaryl, 10-membered heteroaryl, 5-membered heterocyclic ring, 6-membered heterocyclic ring, 7-membered heterocyclic ring, 8-membered heterocyclic ring, 9-membered heterocyclic ring or 10-membered heterocyclic ring; wherein each of the ring system contains 1, 2 or 3 heteroatoms select from N, O or S, and is independently optionally substituted with halogen, -CN, -OH, carbonyl, =O, oxo, -NH2, C1-3alkoxy or C1-3alkyl.
- The compound of any one of claims 1-30, wherein X is O, S or absent.
- The compound of any one of claims 1-31, wherein Y1 is N and Y2 is CR2.
- The compound of any one of claims 1-32, wherein Y2 is N and Y1 is CR1.
- The compound of any one of claims 1-33, wherein R4 is -NH2.
- The compound of any one of claims 1-35, wherein each R8 and R9 is independently -H, halogen, CN, -OH, -NO2, -NH2, -C1-6alkylene-NH2, -C1-6alkylene-NH-C1-6alkyl, -C1-6alkylene-N (C1-6alkyl) 2, -NHBoc, -CH2NHBoc; -NH-C1-6alkyl, -N (C1-6alkyl) 2, -NH-C1-6alkoxy, -N (C1-6alkoxy) 2, C1-6alkyl, C1-6alkoxy, C2-6alkenyl, C2-6alkylnyl, C5-10heterocyclic or C5-10carbocyclic; each of which may be optionally substituted.
- The compound of any one of claims 1-36, wherein each R8 and R9 is independently -H, -F, -Cl, -CN, -OH, -NO2, -NH2, -C1-3alkylene-NH2, -C1-3alkylene-NH-C1-3alkyl, -C1-3alkylene-N (C1-3alkyl) 2, -NHBoc, -CH2NHBoc; -NH-C1-3alkyl, -N (C1-3alkyl) 2, -NH-C1-3alkoxy, -N (C1-3alkoxy) 2, C1-4alkyl, C1-3alkoxy, C2-3alkenyl, C2-3alkylnyl, 5-membered heterocyclic, 6-membered heterocyclic, 7-membered heterocyclic, 8-membered heterocyclic, 9-membered heterocyclic, 10-membered heterocyclic, 5-membered carbocyclic, 6-membered carbocyclic, 7-membered carbocyclic, 8-membered carbocyclic, 9-membered carbocyclic, 10-membered carbocyclic, 5-membered carbocyclic, 6-membered carbocyclic, 7-membered carbocyclic, 8-membered carbocyclic, 9-membered carbocyclic, or 10-membered carbocyclic; and each of which may be independently optionally substituted with halogen, -CN, -OH, -NH2, -N3, -NO2, -C1-6alkylene-NH2, -C1-6alkylene-NH-C1-6alkyl, -C1-6alkylene-N (C1-6alkyl) 2, -NHBoc, -CH2NHBoc; -NH-C1-6alkyl, -N (C1-6alkyl) 2, -NH-C1-6alkoxy, -N (C1-6alkoxy) 2, substituted or unsubstituted C1-6alkyl, or substituted or unsubstituted C1-6alkoxy; and each heterocyclic contains 1, 2, 3 or 4 heteroatoms select from N, O or S.
- The compound of any one of claims 1-38, whereinthe compound is of Formula II:wherein,X is absent or S;Y1 is N or CR25;Y2 is N or C;R25 is H, halogen, C1-3alkyl, C1-3alkoxy, C2-3alkenyl or C2-3alkylnyl;ringis 5-8 member heteUoaryl containing 1, 2, 3 or 4 heteroatoms select form N, O or S, 5-8 member carbocyclic or 5-8 member heterocyclic ring containing 1, 2, 3 or 4 heteroatoms select form N, O or S;R31 is -H, halogen, -OH, -NH2, - (C=O) C1-3alkyl, -CN, -NO2, carbonyl, =O, oxo, carboxyl, -C1-3alkylene-NH2, -C1-3alkylene-NH-C1-3alkyl, -C1-3alkylene-N (C1-3alkyl) 2, -NHBoc, -CH2NHBoc; -NH-C1-3alkyl, -N (C1-3alkyl) 2, -NH-C1-3alkoxy, -N (C1-3alkoxy) 2, substituted or unsubstituted C1-3alkyl, or substituted or unsubstituted C1-3alkoxy;m is 0, 1, 2, 3 or 4;R4 is -H, halogen, -NH2, substituted or unsubstituted C1-3alkoxy, or substituted or unsubstituted C1-3alkyl;each R32 and R33 is independently -H, halogen, -OH, -NH2, -CN, -NO2, -C1-3alkylene-NH2, -C1-3alkylene-NH-C1-3alkyl, -C1-3alkylene-N (C1-3alkyl) 2, -NHBoc, -CH2NHBoc; -NH-C1-3alkyl, -N (C1-3alkyl) 2, -NH-C1-3alkoxy, -N (C1-3alkoxy) 2, substituted or unsubstituted C1-3alkyl, or substituted or unsubstituted C1-3alkoxy;or R32 and R33 together with the carbon atom to which they are both attached form a 5-8 member heteroaryl containing 1, 2 or 3 heteroatoms select from N, O or S, or 5-8 member heterocyclic ring containing 1, 2 or 3 heteroatoms select from N, O or S, wherein each of the ring systems is optionally substituted with halogen, -CN, -OH, -NH2, carbonyl, =O, oxo, -CH2NH2, -C1-3alkylene-NH2, -C1-3alkylene-NH-C1-3alkyl, -C1-3alkylene-N (C1-3alkyl) 2, -NHBoc, -CH2NHBoc; -NH-C1-3alkyl, -N (C1-3alkyl) 2, -NH-C1-3alkoxy, -N (C1-3alkoxy) 2, substituted or unsubstituted C1-3alkyl, or substituted or unsubstituted C1-3alkoxy.
- The compound of claim 39, wherein ringis 5-membered heteroaryl, 6-membered heteroaryl, 7-membered heteroaryl, 5-membered heterocyclic ring, 6-membered heterocyclic ring, 7-membered heterocyclic ring, 5-membered carbocyclic, 6-membered carbocyclic, 7-membered carbocyclic or 8-membered carbocyclic; and each the ring systems contains 1, 2 or 3 heteroatoms select form N, O or S.
- The compound of any one of claims 39-41, wherein R31 is -H, -F, -Cl, -Br, -I, -OH, -NH2, carbonyl, =O, oxo, - (CO) C1-3alkyl, -C1-3alkylene-NH2, -NHBoc, -CH2NHBoc, -NH-C1-3alkyl, -N (C1-3alkyl) 2, substituted or unsubstituted C1-3alkyl, or substituted or unsubstituted C1-3alkoxy.
- The compound of any one of claims 39-42, wherein R31 is -F, -COCH3, carbonyl, =O, oxo, -CH3 or -CF3.
- The compound of claim 39-43, wherein R32 and R33 together with the carbon atom to which they are both attached to form a 5-membered heteroaryl, 6-membered heteroaryl, 7-membered heteroaryl, 5-membered heterocyclic ring, 6-membered heterocyclic ring or 7-membered heterocyclic ring; wherein each of the ring systems contains 1, 2 or 3 heteroatoms select from N, O or S, and is optionally substituted with halogen, -CN, -OH, -NH2, carbonyl, =O, oxo, -CH2NH2, -C1-3alkylene-NH2, -C1-3alkylene-NH-C1-3alkyl, -C1-3alkylene-N (C1-3alkyl) 2, -NHBoc, -CH2NHBoc; -NH-C1-3alkyl, -N (C1-3alkyl) 2, -NH-C1-3alkoxy, -N (C1-3alkoxy) 2, substituted or unsubstituted C1-3alkyl, or substituted or unsubstituted C1-3alkoxy.
- The compound of any one of claims 39-44, wherein R32 and R33 together with the carbon atom to which they are both attached to form a 5-membered heterocyclic ring, 6-membered heterocyclic ring or 7-membered heterocyclic ring; wherein each of the ring system containing 1 or 2 heteroatoms independently select from O or N, and is optionally substituted with halogen, -CN, -OH, -NH2, carbonyl, =O, oxo, carboxyl, -N3, -NO2, C1-3alkyl or C1-3alkoxy.
- The compound of any one of claims 39-45, wherein R32 and R33 together with the carbon atom to which they are both attached to form a 5-membered heterocyclic ring; and the heterocyclic ring contains 1 heteroatoms selected from O or N, and is optionally substituted with –F, -Cl, -OH, -NH2, carbonyl, =O, oxo, methyl or methoxy.
- The compound of any one of claims 39-43, wherein each R32 and R33 is independently -CH2NH2, -CH2NHBoc or methyl.
- The compound of any one of claims 39-47, wherein Y1 is N.
- The compound of any one of claims 39-48, wherein Y2 is C.
- The compound of any one of claims 39-49, wherein R25 is -H or –Cl.
- The compound of any one of claims 39-50, wherein R4 is -NH2.
- The compound of any one of claims 1-38, wherein the compound is of Formula III:wherein,X is absent or S;R26 is -H, halogen, substituted or unsubstituted C1-3alkyl, or substituted or unsubstituted C1-3alkoxy;ringis 5-8 member heteroaryl or 5-8 member heterocyclic ring; and each the ring system independently contains 1, 2, 3 or 4 heteroatoms select form N, O or S;R34 is -H, halogen, -OH, -NR35R36, -CN, -NO2, carbonyl, =O, oxo, substituted or unsubstituted C1-3alkyl, or substituted or unsubstituted C1-3alkoxy;n is 0, 1, 2 or 3;R4 is -H, halogen, -NH2, substituted or unsubstituted C1-6alkoxy, or substituted or unsubstituted C1-6 alkyl;each R35 and R36 is independently -H, halogen, -OH, -NH2, -CN, -NO2, -CH2NH2, substituted or unsubstituted C1-3alkyl, or substituted or unsubstituted C1-3alkoxy;or R35 and R36 together with the carbon atom to which they are both attached to form a 5-8 member heteroaryl or 5-8 member heterocyclic ring, wherein each of the ring system independently contains 1, 2 or 3 heteroatoms select from N, O or S, and is optionally substituted with halogen, -CN, -OH, -NH2, carbonyl, =O, oxo, -CH2NH2, -C1-3alkylene-NH2, -C1-3alkylene-NH-C1-3alkyl, -C1-3alkylene-N (C1-3alkyl) 2, -NHBoc, -CH2NHBoc; -NH-C1-3alkyl, -N (C1-3alkyl) 2, -NHC1-3alkoxy, -N (C1-3alkoxy) 2, substituted or unsubstituted C1-3alkyl, or substituted or unsubstituted C1-3alkoxy.
- The compound of any one of claims 52-54, wherein R35 and R36 together with the carbon atom to which they are both attached to form a 5-membered heteroaryl, 6-membered heteroaryl, 7-membered heteroaryl, 5-membered heterocyclic ring, 6-membered heterocyclic ring or 7-membered heterocyclic ring; wherein each of the ring system is independently contains 1, 2 or 3 heteroatoms select from N, O or S, and is optionally substituted with halogen, -CN, -OH, -NH2, carbonyl, =O, oxo, -CH2NH2, -C1-3alkylene-NH2, -C1-3alkylene-NH-C1-3alkyl, -C1-3alkylene-N (C1-3alkyl) 2, -NHBoc, -CH2NHBoc; -NH-C1-3alkyl, -N (C1-3alkyl) 2, -NHC1-3alkoxy, -N (C1-3alkoxy) 2, substituted or unsubstituted C1-3alkyl, or substituted or unsubstituted C1-3alkoxy.
- The compound of any one of claims 52-55, wherein R35 and R36 together with the carbon atom to which they are both attached to form a 5-membered heterocyclic ring, 6-membered heterocyclic ring or 7-membered heterocyclic ring; wherein each of the ring system is independently contains 1 or 2 heteroatoms independently select from O or N, and is optionally substituted with halogen, -CN, -OH, -NH2, carbonyl, =O, oxo, carboxyl, -N3, -NO2, C1-3alkyl or C1-3alkoxy.
- The compound of any one of claims 52-56, wherein R35 and R36 together with the carbon atom to which they are both attached to form a 5-membered heterocyclic ring; wherein the ring system contains 1 heteroatom independently select from O or N, and is optionally substituted with –F, -Cl, -OH, -NH2, carbonyl, =O, oxo, methyl or methoxy.
- The compound of any one of claims 52-57, wherein R26 is -H or -Cl.
- The compound of any one of claims 52-58, wherein R4 is -NH2.
- The compound of any one of claims 52-59, wherein R34 is -F, -COCH3, carbonyl, =O, oxo, -CH3 or -CF3.
- The compound of any one of claims 1-60, wherein each substituted or unsubstituted C1-6alkyl is independently C1-6alkyl, or C1-6alkyl substituted with halogen, -OH, -CN, NH2, -NO2, carbonyl, =O, oxo, -C1-6alkylene-NH2, -C1-6alkylene-NH-C1-6alkyl. or -C1-6alkylene-N (C1-6alkyl) 2; each substituted or unsubstituted C1-6alkoxy is independently C1-6alkoxy, or C1-6alkoxy substituted with halogen, -OH, -CN, NH2, -NO2, carbonyl, =O, oxo, -C1-6alkylene-NH2, -C1-6alkylene-NH-C1-3alkyl or -C1-6alkylene-N (C1-6alkyl) 2.
- The compound of any one of claims 1-61, wherein each substituted or unsubstituted C1-3alkyl is independently C1-3alkyl, or C1-3alkyl substituted with halogen, -OH, -CN, NH2, -NO2, carbonyl, =O, oxo, -C1-3alkylene-NH2, -C1-3alkylene-NH-C1-3alkyl, or -C1-3alkylene-N (C1-3alkyl) 2; each substituted or unsubstituted C1-3alkoxy is independently C1-3alkoxy, or C1-3alkoxy substituted with halogen, -OH, -CN, NH2, -NO2, carbonyl, =O, oxo, -C1-3alkylene-NH2, -C1-3alkylene-NH-C1-3alkyl, or -C1-3alkylene-N (C1-3alkyl) 2.
- The compound of any one of claims 1-62, wherein each C1-6alkyl is independently methyl, ethyl, propyl, isopropyl, cyclopropyl, n-butyl, isobutyl, tert-buyl, n-pentyl, neopentyl, isopentyl, cyclopentyl, n-hexyl or cyclohexyl.
- The compound of any one of claims 1-63, wherein each C1-3alkyl is independently methyl, ethyl, propyl, isopropyl or cyclopropyl.
- The compound of any one of claims 1-64, wherein each C1-3alkoxy is independently methoxy, ethoxy, propoxy, isopropoxy or cyclopropyloxy.
- The compound of any one of claims 1-65, wherein each C2-3alkenyl is independently -CH=CH2, -CH2-CH=CH2 or -CH=CH-CH3.
- The compound of any one of claims 1-66, wherein each C2-3alkylnyl is independently -C≡CH, -CH2-C≡CH or -C≡C-CH3.
- The compound of any one of claims 1-67, wherein each halogen is independently -F, -Cl, -Br or -I.
- The compound of any one of claims 1-68, wherein each heterocyclic group and each carbocyclic group includes single ring, spiral ring, bridge ring, fused ring and all various combinations of spiral ring, bridge ring, and/or fused ring.
- The compound of claim 1, wherein the compound is1) (S) -N1- (3- ( (3-amino-5- (4-amino-2-oxa-8-azaspiro [4.5] decan-8-yl) pyrazin-2-yl) thio) -2-chlorophenyl) -N2, N2-dimethyloxalamide hydrochloride;2) N1- (4- ( (3-amino-5- (4-amino-4-methylpiperidin-1-yl) pyrazin-2-yl) thio) -3-chloropyrid in-2-yl) -N2, N2-dimethyloxalamide;3) N- (3- ( (3-amino-5- (4-amino-4-methylpiperidin-1-yl) pyrazin-2-yl) thio) -2-chloropheny l) -4- (2- (dimethylamino) -2-oxoacetyl) benzamide;4) 6- ( (3-amino-5- (4- (aminomethyl) -4-methylpiperidin-1-yl) pyrazin-2-yl) thio) -2H-benz o [b] [1, 4] oxazin-3 (4H) -one;5) 6- (3-amino-5- (4- (aminomethyl) -4-methylpiperidin-1-yl) pyrazin-2-yl) -2H-benzo [b] [1 , 4] oxazin-3 (4H) -one;6) 5- ( (2-amino-3-chloropyridin-4-yl) thio) -N2- (2-azaspiro [4.5] decan-8-yl) pyrazine-2, 6-diamine;7) (S) -1- (4- ( (3-amino-5- (4-amino-2-oxa-8-azaspiro [4.5] decan-8-yl) pyrazin-2-yl) thio) -3 , 3-difluoroindolin-1-yl) ethanone;8) (S) -4- ( (3-amino-5- (4-amino-2-oxa-8-azaspiro [4.5] decan-8-yl) pyrazin-2-yl) thio) -3, 3-difluoroindolin-2-one;9) 4- ( (3-amino-5- (4- (aminomethyl) -4-methylpiperidin-1-yl) pyrazin-2-yl) thio) indolin-2-one;10) (S) -4- ( (3-amino-5- (4-amino-2-oxa-8-azaspiro [4.5] decan-8-yl) pyrazin-2-yl) thio) -3, 3-difluoro-1H-pyrrolo [2, 3-b] pyridin-2 (3H) -one;11) (R) -N- ( (S) -8- (6-amino-5- ( (3, 3-difluoro-1-methyl-2-oxoindolin-4-yl) thio) pyrazin-2-y l) -2-oxa-8-azaspiro [4.5] decan-4-yl) -2-methylpropane-2-sulfinamide;12) (S) -4- ( (3-amino-5- (4-amino-2-oxa-8-azaspiro [4.5] decan-8-yl) pyrazin-2-yl) thio) indol ine-2, 3-dione hydrochloride;13) tert-butyl ( (1- (5- ( (1-acetyl-3, 3-difluoroindolin-4-yl) thio) -6-aminopyrazin-2-yl) -4-methylpiperidin-4-yl) methyl) carbamate;14) 4- ( (3-amino-5- (4- (aminomethyl) -4-methylpiperidin-1-yl) pyrazin-2-yl) thio) indoline-2 , 3-dione;15) 5- ( (2-amino-3-chloropyridin-4-yl) thio) -6- (4- (aminomethyl) -4-methylpiperidin-1-yl) p yrazin-2-amine;16) N1- (4- ( (3-amino-5- (4- (aminomethyl) -4-methylpiperidin-1-yl) pyrazin-2-yl) thio) -3-chl oropyridin-2-yl) -N2, N2-dimethyloxalamide ;17) tert-butyl ( (1- (6-amino-5- ( (2-amino-3-chloropyridin-4-yl) thio) pyrazin-2-yl) -4-methylpiperidin-4-yl) methyl) carbamate;18) (S) -N1- (4- ( (3-amino-5- (4-amino-2-oxa-8-azaspiro [4.5] decan-8-yl) pyrazin-2-yl) thio) -3-chloropyridin-2-yl) -N2, N2-dimethyloxalamide;19) (S) -N1- (3- ( (3-amino-5- (4-amino-2-oxa-8-azaspiro [4.5] decan-8-yl) pyrazin-2-yl) thio) -2-chlorophenyl) -N2, N2-dimethyloxalamide;20) N1- (3- ( (3-amino-5- (4- (aminomethyl) -4-methylpiperidin-1-yl) pyrazin-2-yl) thio) -2-chl orophenyl) -N2, N2-dimethyloxalamide;21) N- (3- ( (3-amino-5- (4- (aminomethyl) -4-methylpiperidin-1-yl) pyrazin-2-yl) thio) -2-chl orophenyl) -3- (2- (dimethylamino) -2-oxoacetyl) benzamide;22) 2- (3- (3- (3- ( (3-amino-5- (4- (aminomethyl) -4-methylpiperidin-1-yl) pyrazin-2-yl) thio) -2-chlorophenyl) ureido) phenyl) -N, N-dimethyl-2-oxoacetamide;23) 2- (4- (3- (3- ( (3-amino-5- (4- (aminomethyl) -4-methylpiperidin-1-yl) pyrazin-2-yl) thio) -2-chlorophenyl) ureido) phenyl) -N, N-dimethyl-2-oxoacetamide;24) 6- (4- (aminomethyl) -4-methylpiperidin-1-yl) -3- ( (3, 4-dihydro-2H-benzo [b] [1, 4] oxazi n-6-yl) thio) pyrazin-2-amine;25) tert-butyl (1- (6-amino-5- ( (2-amino-3-chloropyridin-4-yl) thio) pyrazin-2-yl) -4-methylpiperidin-4-yl) carbamate;26) tert-butyl (1- (5- ( (2-acrylamido-3-chloropyridin-4-yl) thio) -6-aminopyrazin-2-yl) -4-methylpiperidin-4-yl) carbamate;27) tert-butyl (1- (6-amino-5- ( (3-chloro-2- (2- (dimethylamino) -2-oxoacetamido) pyridin-4 -yl) thio) pyrazin-2-yl) -4-methylpiperidin-4-yl) carbamate;28) tert-butyl (1- (6-amino-5- ( (2-chloro-3- (2- (dimethylamino) -2-oxoacetamido) phenyl) thio) pyrazin-2-yl) -4-methylpiperidin-4-yl) carbamate;29) N1- (3- ( (3-amino-5- (4-amino-4-methylpiperidin-1-yl) pyrazin-2-yl) thio) -2-chlorophen yl)-N2, N2-dimethyloxalamide;30) tert-butyl (1- (6-amino-5- ( (3-amino-2-chlorophenyl) thio) pyrazin-2-yl) -4-methylpiperidin-4-yl) carbamate;31) N- (3- ( (3-amino-5- (4-amino-4-methylpiperidin-1-yl) pyrazin-2-yl) thio) -2-chloropheny l) -2-oxo-2- (p-tolyl) acetamide;32) tert-butyl (1- (5- ( (3-acrylamido-2-chlorophenyl) thio) -6-aminopyrazin-2-yl) -4-methylpiperidin-4-yl) carbamate;33) 6- (3-amino-5- (4-amino-4-methylpiperidin-1-yl) pyrazin-2-yl) -2H-benzo [b] [1, 4] oxazi n-3 (4H) -one;34) N- (4- ( (3-amino-5- (4-amino-4-methylpiperidin-1-yl) pyrazin-2-yl) thio) -3-chloropyridi n-2-yl) -4- (2- (dimethylamino) -2-oxoacetyl) benzamide;35) N- (4- ( (3-amino-5- (4- (aminomethyl) -4-methylpiperidin-1-yl) pyrazin-2-yl) thio) -3-chl oropyridin-2-yl) -4- (2- (dimethylamino) -2-oxoacetyl) benzamide;36) N- (3- ( (3-amino-5- (4- (aminomethyl) -4-methylpiperidin-1-yl) pyrazin-2-yl) thio) -2-chl orophenyl) -4- (2- (dimethylamino) -2-oxoacetyl) benzamide;37) 5- ( (2-amino-3-chloropyridin-4-yl) thio) -N2-cyclohexylpyrazine-2, 6-diamine; -3062-B38) (S) -8- (5- ( (1H-pyrrolo [2, 3-b] pyridin-4-yl) thio) -6-aminopyrazin-2-yl) -2-oxa-8-azaspir o [4.5] decan-4-amine;39) (S) -8- (6-amino-5- ( (3, 3-dimethylindolin-4-yl) thio) pyrazin-2-yl) -2-oxa-8-azaspiro [4.5 ] decan-4-amine;40) (S) -8- (6-amino-5- ( (3-fluoro-1H-indol-4-yl) thio) pyrazin-2-yl) -2-oxa-8-azaspiro [4.5] d ecan-4-amine;41) 5- ( (2-amino-3-chloropyridin-4-yl) thio) -N2- (4- (aminomethyl) -4-methylcyclohexyl) p yrazine-2, 6-diamine;42) (S) -8- (5- ( (1H-indol-4-yl) thio) -6-aminopyrazin-2-yl) -2-oxa-8-azaspiro [4.5] decan-4-amine;43) (S) -1- (4- ( (3-amino-5- (4-amino-2-oxa-8-azaspiro [4.5] decan-8-yl) pyrazin-2-yl) thio) -1 H-indol-1-yl) ethanone;44) 5- ( (2-amino-3-chloropyridin-4-yl) thio) -N2- (4-amino-4-methylcyclohexyl) pyrazine-2 , 6-diamine;45) (S) -6- ( (3-amino-5- (4-amino-2-oxa-8-azaspiro [4.5] decan-8-yl) pyrazin-2-yl) thio) -2H-benzo [b] [1, 4] oxazin-3 (4H) -one;46) (S) -4- ( (3-amino-5- (4-amino-2-oxa-8-azaspiro [4.5] decan-8-yl) pyrazin-2-yl) thio) -1, 3, 3-trimethylindolin-2-one;47) (4S) -8- (6-amino-5- ( (3-fluoroindolin-4-yl) thio) pyrazin-2-yl) -2-oxa-8-azaspiro [4.5] de can-4-amine;48) 1- (4- ( (3-amino-5- ( (S) -4-amino-2-oxa-8-azaspiro [4.5] decan-8-yl) pyrazin-2-yl) thio) -3 -fluoro-3-methylindolin-1-yl) ethanone;49) (S) -8- (6-amino-5- ( (3, 3-difluoroindolin-4-yl) thio) pyrazin-2-yl) -2-oxa-8-azaspiro [4.5] decan-4-amine;50) 1- (4- ( (3-amino-5- ( (S) -4-amino-2-oxaspiro [4.5] decan-8-yl) pyrazin-2-yl) thio) -3-meth ylindolin-1-yl) ethanone;51) (S) -8- (6-amino-5- ( (8-chloro-4, 4-difluoro-1, 2, 3, 4-tetrahydroquinolin-5-yl) thio) pyrazi n-2-yl) -2-oxa-8-azaspiro [4.5] decan-4-amine;52) (4S) -8- (6-amino-5- ( (8-chloro-4-fluoro-1, 2, 3, 4-tetrahydroquinolin-5-yl) thio) pyrazin-2 -yl) -2-oxa-8-azaspiro [4.5] decan-4-amine;53) (S) -8- (6-amino-5- ( (3, 3-difluoro-1-methylindolin-4-yl) thio) pyrazin-2-yl) -2-oxa-8-aza spiro [4.5] decan-4-amine;54) (S) -6- ( (3-amino-5- (4-amino-2-oxa-8-azaspiro [4.5] decan-8-yl) pyrazin-2-yl) thio) -3, 3-difluoroindolin-2-one;55) 4- ( (3-amino-5- ( (S) -4-amino-2-oxa-8-azaspiro [4.5] decan-8-yl) pyrazin-2-yl) thio) -3-fl uoroindolin-2-one;56) (S) -8- (6-amino-5- ( (3, 3-difluoro-2, 3-dihydrobenzofuran-4-yl) thio) pyrazin-2-yl) -2-ox a-8-azaspiro [4.5] decan-4-amine;57) (S) -8- (6-amino-5- ( (4, 4-difluorochroman-5-yl) thio) pyrazin-2-yl) -2-oxa-8-azaspiro [4. 5] decan-4-amine;58) 4- ( (3-amino-5- ( (S) -4-amino-2-oxa-8-azaspiro [4.5] decan-8-yl) pyrazin-2-yl) thio) -3-fl uoro-1-methyl-3- (trifluoromethyl) indolin-2-one;59) (S) -6- ( (3-amino-5- (4-amino-2-oxa-8-azaspiro [4.5] decan-8-yl) pyrazin-2-yl) thio) -7-ch loroindolin-2-one;60) (S) -8- (6-amino-5- ( (5-chloro-3, 4-dihydro-2H-benzo [b] [1, 4] oxazin-6-yl) thio) pyrazin-2-yl) -2-oxa-8-azaspiro [4.5] decan-4-amine;61) (S) -7- ( (3-amino-5- (4-amino-2-oxa-8-azaspiro [4.5] decan-8-yl) pyrazin-2-yl) thio) -8-ch loro-3, 4-dihydroquinolin-2 (1H) -one;62) (S) -6- ( (3-amino-5- (4-amino-2-oxa-8-azaspiro [4.5] decan-8-yl) pyrazin-2-yl) thio) -5-ch loro-2H-benzo [b] [1, 4] oxazin-3 (4H) -one;63) (S) -2- (3- ( (3-amino-5- (4-amino-2-oxa-8-azaspiro [4.5] decan-8-yl) pyrazin-2-yl) thio) -2 -chlorophenyl) -N, N-dimethyl-2-oxoacetamide;64) 4- ( (3-amino-5- (4- (aminomethyl) -4-methylpiperidin-1-yl) pyrazin-2-yl) thio) -3, 3-diflu oro-1H-pyrrolo [2, 3-b] pyridin-2 (3H) -one;65) (S) -4- ( (3-amino-5- (4-amino-2-oxa-8-azaspiro [4.5] decan-8-yl) pyrazin-2-yl) thio) -1H-benzo [d] imidazol-2 (3H) -one;66) (S) -4- ( (3-amino-5- (4-amino-2-oxa-8-azaspiro [4.5] decan-8-yl) pyrazin-2-yl) thio) -1, 3-dimethyl-1H-benzo [d] imidazol-2 (3H) -one;67) (S) -8- (6-amino-5- ( (2, 2-difluoro-2, 3-dihydro-1H-benzo [d] imidazol-4-yl) thio) pyrazin-2-yl) -2-oxa-8-azaspiro [4.5] decan-4-amine;68) (S) -8- (6-amino-5- ( (2, 2-difluoro-1, 3-dimethyl-2, 3-dihydro-1H-benzo [d] imidazol-4-yl ) thio) pyrazin-2-yl) -2-oxa-8-azaspiro [4.5] decan-4-amine;69) (4S) -8- (6-amino-5- ( (1-amino-3, 3-difluoro-2, 3-dihydro-1H-inden-4-yl) thio) pyrazin-2 -yl) -2-oxa-8-azaspiro [4.5] decan-4-amine;70) (S) -5- ( (3-amino-5- (4-amino-2-oxa-8-azaspiro [4.5] decan-8-yl) pyrazin-2-yl) thio) -2-m ethyl- [1, 2, 4] triazolo [4, 3-a] pyridin-3 (2H) -one;71) (S) -8- (6-amino-5- ( (3, 3-difluoro-2-methyl-2, 3-dihydro- [1, 2, 4] triazolo [4, 3-a] pyridin-5 -yl) thio) pyrazin-2-yl) -2-oxa-8-azaspiro [4.5] decan-4-amine;72) (S) -1- (4- ( (3-amino-5- (4-amino-2-oxa-8-azaspiro [4.5] decan-8-yl) pyrazin-2-yl) thio) in dolin-1-yl) ethanone;73) 1'- (6-amino-5- ( (2-amino-3-chloropyridin-4-yl) thio) pyrazin-2-yl) hexahydrospiro [cycl openta [b] furan-5, 4'-piperidin] -4-amine;74) 1'- (6-amino-5- ( (2-amino-3-chloropyridin-4-yl) thio) pyrazin-2-yl) spiro [bicyclo [3.1.0] hexane-3, 4'-piperidin] -2-amine;75) 1'-amino-1- (6-amino-5- ( (2-amino-3-chloropyridin-4-yl) thio) pyrazin-2-yl) tetrahydros piro [piperidine-4, 2'-pyrrolizin] -3' (1'H) -one;76) 1'- (6-amino-5- ( (2-amino-3-chloropyridin-4-yl) thio) pyrazin-2-yl) spiro [bicyclo [3.1.0] hexane-2, 4'-piperidin] -3-amine.
- A pharmaceutical composition comprising at least one compound as defined in any one of claims 1-71 and at least one pharmaceutically acceptable excipient.
- The pharmaceutical composition according to claim 72, wherein, the said compound in a weight ratio to the said excipient within the range from about 0.0001 to about 10.
- Use of a pharmaceutical composition of as defined in claim 72 or 73 for the preparation of a medicament.
- The use according to claim 74 for the preparation of a medicament for the treatment or prevention of cancer, cancer metastasis, cardiovascular disease, an immunological disorder or an ocular disorder.
- Use of at least one compound of any one of claims 1-71 is to prepare of a medicament.
- The use according to claim 76 for the preparation of a medicament for the treatment or prevention of cancer, cancer metastasis, cardiovascular disease, an immunological disorder or an ocular disorder.
- At least one compound for use as defined in any one of claims 1-71, which is for use in the treatment of cancer, the prevention of cancer metastasis or the treatment of cardiovascular disease, an immunological disorder or an ocular disorder.
- Use, in the manufacture of a medicament for use as an inhibitor of SHP2, of at least one compound as defined in any one of claims 1-71.
- A method of treating a patient having a condition which is mediated by the activity of SHP2, said method comprising administering to the patient a therapeutically effective amount of at least one compound as defined in any one of claims 1-71, or a pharmaceutically acceptable salt thereof.
- The method according to claim 80 wherein the condition mediated by the activity of SHP2 is cancer.
- The method according to claim 80, wherein the condition mediated by the activity of SHP2 is noonan syndrome, leopard syndrome, juvenile myelomonocytic leukemias, liver cancer, neuroblastoma, melanoma, squamous-cell carcinoma of the head and neck, acute myeloid leukemia, breast cancer, esophageal cancer, lung cancer, colon cancer, head cancer, gastric carcinoma, neuroblastoma, anaplastic large-cell lymphoma and glioblastoma.
- At least one compound as defined in any one of claims 1-71 or a pharmaceutically acceptable salt thereof for use as a medicament.
- At least one compound according to any one of claims 1-71 or a pharmaceutically acceptable salt thereof for use in the treatment of cancer.
- A method of treating cancer selected from the group consisting of noonan syndrome, leopard syndrome, juvenile myelomonocytic leukemias, liver cancer, neuroblastoma, melanoma, squamous-cell carcinoma of the head and neck, acute myeloid leukemia, breast cancer, esophageal cancer, lung cancer, colon cancer, head cancer, gastric carcinoma, neuroblastoma, anaplastic large-cell lymphoma and glioblastoma in a mammal comprising administering to a mammal in need of such treatment an effective amount of at least one compound as defined in any one of claims 1-71 or a pharmaceutically acceptable salt thereof.
Priority Applications (25)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SI201731100T SI3464272T1 (en) | 2016-06-07 | 2017-06-07 | Novel heterocyclic derivatives useful as shp2 inhibitors |
MX2018015297A MX2018015297A (en) | 2016-06-07 | 2017-06-07 | Novel heterocyclic derivatives useful as shp2 inhibitors. |
KR1020227029335A KR20220124275A (en) | 2016-06-07 | 2017-06-07 | Novel heterocyclic derivatives useful as SHP2 inhibitors |
JP2019517133A JP6751203B2 (en) | 2016-06-07 | 2017-06-07 | Novel heterocyclic derivatives useful as SHP2 inhibitors |
LTEPPCT/CN2017/087471T LT3464272T (en) | 2016-06-07 | 2017-06-07 | Novel heterocyclic derivatives useful as shp2 inhibitors |
KR1020217004404A KR20210019607A (en) | 2016-06-07 | 2017-06-07 | Novel heterocyclic derivatives useful as shp2 inhibitors |
PL17809742T PL3464272T3 (en) | 2016-06-07 | 2017-06-07 | Novel heterocyclic derivatives useful as shp2 inhibitors |
KR1020197000391A KR102218333B1 (en) | 2016-06-07 | 2017-06-07 | Novel heterocyclic derivatives useful as SHP2 inhibitors |
AU2017276457A AU2017276457B2 (en) | 2016-06-07 | 2017-06-07 | Novel heterocyclic derivatives useful as SHP2 inhibitors |
KR1020237022188A KR20230109185A (en) | 2016-06-07 | 2017-06-07 | Novel heterocyclic derivatives useful as shp2 inhibitors |
SG11201810983PA SG11201810983PA (en) | 2016-06-07 | 2017-06-07 | Novel heterocyclic derivatives useful as shp2 inhibitors |
EP21212393.9A EP4108659A1 (en) | 2016-06-07 | 2017-06-07 | Novel heterocyclic derivatives useful as shp2 inhibitors |
RS20220205A RS62987B1 (en) | 2016-06-07 | 2017-06-07 | Novel heterocyclic derivatives useful as shp2 inhibitors |
HRP20220251TT HRP20220251T1 (en) | 2016-06-07 | 2017-06-07 | Novel heterocyclic derivatives useful as shp2 inhibitors |
CN201780035294.3A CN109311848B (en) | 2016-06-07 | 2017-06-07 | Novel heterocyclic derivatives useful as SHP2 inhibitors |
EA201990001A EA201990001A1 (en) | 2016-06-07 | 2017-06-07 | NEW HETEROCYCLIC DERIVATIVES APPLICABLE AS SHP2 INHIBITORS |
ES17809742T ES2908801T3 (en) | 2016-06-07 | 2017-06-07 | Novel heterocyclic derivatives useful as SHP2 inhibitors |
EP17809742.4A EP3464272B1 (en) | 2016-06-07 | 2017-06-07 | Novel heterocyclic derivatives useful as shp2 inhibitors |
CN202210183947.5A CN114539273A (en) | 2016-06-07 | 2017-06-07 | Novel heterocyclic derivatives useful as SHP2 inhibitors |
KR1020217037106A KR20210141778A (en) | 2016-06-07 | 2017-06-07 | Novel heterocyclic derivatives useful as shp2 inhibitors |
CA3026784A CA3026784A1 (en) | 2016-06-07 | 2017-06-07 | Heterocyclic pyrazine derivatives useful as shp2 inhibitors |
US16/307,827 US10858359B2 (en) | 2016-06-07 | 2017-06-07 | Heterocyclic ring derivatives useful as SHP2 inhibitors |
DK17809742.4T DK3464272T3 (en) | 2016-06-07 | 2017-06-07 | New heterocyclic derivatives as SHP2 inhibitors |
PH12018550202A PH12018550202A1 (en) | 2016-06-07 | 2018-12-07 | Novel heterocyclic derivatives useful as shp2 inhibitors |
CY20221100180T CY1125042T1 (en) | 2016-06-07 | 2022-03-02 | NEW HETEROCYCLIC DERIVATIVES USABLE AS SHP2 INHIBITORS |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2016085122 | 2016-06-07 | ||
CNPCT/CN2016/085122 | 2016-06-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017211303A1 true WO2017211303A1 (en) | 2017-12-14 |
Family
ID=60578379
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2017/087471 WO2017211303A1 (en) | 2016-06-07 | 2017-06-07 | Novel heterocyclic derivatives useful as shp2 inhibitors |
Country Status (23)
Country | Link |
---|---|
US (1) | US10858359B2 (en) |
EP (2) | EP3464272B1 (en) |
JP (3) | JP6751203B2 (en) |
KR (5) | KR20210141778A (en) |
CN (3) | CN109311848B (en) |
AU (1) | AU2017276457B2 (en) |
CA (1) | CA3026784A1 (en) |
CY (1) | CY1125042T1 (en) |
DK (1) | DK3464272T3 (en) |
EA (3) | EA201990001A1 (en) |
ES (1) | ES2908801T3 (en) |
HR (1) | HRP20220251T1 (en) |
HU (1) | HUE057838T2 (en) |
LT (1) | LT3464272T (en) |
MA (1) | MA45189A (en) |
MX (3) | MX2018015297A (en) |
PH (1) | PH12018550202A1 (en) |
PL (1) | PL3464272T3 (en) |
PT (1) | PT3464272T (en) |
RS (1) | RS62987B1 (en) |
SG (2) | SG11201810983PA (en) |
SI (1) | SI3464272T1 (en) |
WO (1) | WO2017211303A1 (en) |
Cited By (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018172984A1 (en) | 2017-03-23 | 2018-09-27 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as shp2 inhibitors |
WO2019051084A1 (en) | 2017-09-07 | 2019-03-14 | Revolution Medicines, Inc. | Shp2 inhibitor compositions and methods for treating cancer |
CN110143949A (en) * | 2018-05-09 | 2019-08-20 | 北京加科思新药研发有限公司 | It can be used as the new type heterocycle derivative of SHP2 inhibitor |
WO2019158019A1 (en) | 2018-02-13 | 2019-08-22 | 上海青煜医药科技有限公司 | Pyrimidine-fused cyclic compound, preparation method therefor and application thereof |
WO2019183367A1 (en) * | 2018-03-21 | 2019-09-26 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
US10435389B2 (en) | 2017-09-11 | 2019-10-08 | Krouzon Pharmaccuticals, Inc. | Octahydrocyclopenta[c]pyrrole allosteric inhibitors of SHP2 |
WO2019199792A1 (en) | 2018-04-10 | 2019-10-17 | Revolution Medicines, Inc. | Shp2 inhibitor compositions, methods for treating cancer and methods for identifying a subject with shp2 mutations |
US10561655B2 (en) | 2018-03-21 | 2020-02-18 | Synblia Therapeutics, Inc. | SHP2 inhibitors and uses thereof |
US10590090B2 (en) | 2016-07-12 | 2020-03-17 | Revolution Medicines, Inc. | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors |
WO2020061101A1 (en) * | 2018-09-18 | 2020-03-26 | Nikang Therapeutics, Inc. | Tri-substituted heteroaryl derivatives as src homology-2 phosphatase inhibitors |
WO2020065452A1 (en) * | 2018-09-29 | 2020-04-02 | Novartis Ag | Manufacture of compounds and compositions for inhibiting the activity of shp2 |
WO2020063760A1 (en) * | 2018-09-26 | 2020-04-02 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as shp2 inhibitors |
WO2020065453A1 (en) * | 2018-09-29 | 2020-04-02 | Novartis Ag | Process of manufacture of a compound for inhibiting the activity of shp2 |
WO2020073949A1 (en) * | 2018-10-10 | 2020-04-16 | 江苏豪森药业集团有限公司 | Regulator of nitrogen-containing heteroaromatic derivatives, preparation method therefor and use thereof |
WO2020076723A1 (en) | 2018-10-08 | 2020-04-16 | Revolution Medicines, Inc. | Shp2 inhibitor compositions for use in treating cancer |
WO2020081848A1 (en) | 2018-10-17 | 2020-04-23 | Array Biopharma Inc. | Protein tyrosine phosphatase inhibitors |
CN111138412A (en) * | 2018-11-06 | 2020-05-12 | 上海奕拓医药科技有限责任公司 | Spiro aromatic ring compound and application thereof |
WO2020108590A1 (en) | 2018-11-30 | 2020-06-04 | 上海拓界生物医药科技有限公司 | Pyrimidine and five-membered nitrogen heterocycle derivative, preparation method therefor, and medical uses thereof |
WO2020180768A1 (en) | 2019-03-01 | 2020-09-10 | Revolution Medicines, Inc. | Bicyclic heteroaryl compounds and uses thereof |
WO2020180770A1 (en) | 2019-03-01 | 2020-09-10 | Revolution Medicines, Inc. | Bicyclic heterocyclyl compounds and uses thereof |
WO2020201991A1 (en) | 2019-04-02 | 2020-10-08 | Array Biopharma Inc. | Protein tyrosine phosphatase inhibitors |
WO2020237025A1 (en) | 2019-05-23 | 2020-11-26 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
US10851110B2 (en) | 2016-05-31 | 2020-12-01 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of PTPN11 |
US10858359B2 (en) | 2016-06-07 | 2020-12-08 | Jacobio Pharmaceuticals Co., Ltd. | Heterocyclic ring derivatives useful as SHP2 inhibitors |
WO2020259679A1 (en) | 2019-06-28 | 2020-12-30 | 上海拓界生物医药科技有限公司 | Pyrimidine five-membered nitrogen heterocyclic derivative, preparation method thereof and pharmaceutical use thereof |
WO2020263830A1 (en) | 2019-06-25 | 2020-12-30 | Gilead Sciences, Inc. | Flt3l-fc fusion proteins and methods of use |
EP3772513A1 (en) | 2019-08-09 | 2021-02-10 | C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening | Shp2 inhibitors |
WO2021033153A1 (en) * | 2019-08-20 | 2021-02-25 | Otsuka Pharmaceutical Co., Ltd. | Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors |
US10934285B2 (en) | 2016-06-14 | 2021-03-02 | Novartis Ag | Compounds and compositions for inhibiting the activity of SHP2 |
US10954243B2 (en) | 2018-05-02 | 2021-03-23 | Navire Pharma, Inc. | Substituted heterocyclic inhibitors of PTPN11 |
WO2021076908A1 (en) | 2019-10-18 | 2021-04-22 | Forty Seven, Inc. | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
WO2021087064A1 (en) | 2019-10-31 | 2021-05-06 | Forty Seven, Inc. | Anti-cd47 and anti-cd20 based treatment of blood cancer |
US11001561B2 (en) | 2019-04-08 | 2021-05-11 | Merck Patent Gmbh | Pyrimidinone derivatives as SHP2 antagonists |
WO2021092115A1 (en) | 2019-11-08 | 2021-05-14 | Revolution Medicines, Inc. | Bicyclic heteroaryl compounds and uses thereof |
WO2021091982A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
WO2021091967A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
WO2021091956A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
WO2021096860A1 (en) | 2019-11-12 | 2021-05-20 | Gilead Sciences, Inc. | Mcl1 inhibitors |
WO2021108683A1 (en) | 2019-11-27 | 2021-06-03 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
US11033547B2 (en) | 2019-03-07 | 2021-06-15 | Merck Patent Gmbh | Carboxamide-pyrimidine derivatives as SHP2 antagonists |
WO2021130638A1 (en) | 2019-12-24 | 2021-07-01 | Carna Biosciences, Inc. | Diacylglycerol kinase modulating compounds |
WO2021142026A1 (en) | 2020-01-07 | 2021-07-15 | Revolution Medicines, Inc. | Shp2 inhibitor dosing and methods of treating cancer |
WO2021143701A1 (en) | 2020-01-19 | 2021-07-22 | 北京诺诚健华医药科技有限公司 | Pyrimidine-4(3h)-ketone heterocyclic compound, preparation method therefor and use thereof in medicine and pharmacology |
WO2021163064A2 (en) | 2020-02-14 | 2021-08-19 | Jounce Therapeutics, Inc. | Antibodies and fusion proteins that bind to ccr8 and uses thereof |
US11104675B2 (en) | 2018-08-10 | 2021-08-31 | Navire Pharma, Inc. | PTPN11 inhibitors |
WO2021171261A1 (en) | 2020-02-28 | 2021-09-02 | Novartis Ag | A triple pharmaceutical combination comprising dabrafenib, an erk inhibitor and a shp2 inhibitor |
WO2021222522A1 (en) | 2020-05-01 | 2021-11-04 | Gilead Sciences, Inc. | Cd73 inhibiting 2,4-dioxopyrimidine compounds |
WO2021218752A1 (en) * | 2020-04-26 | 2021-11-04 | Betta Pharmaceuticals Co., Ltd | Shp2 inhibitors, compositions and uses thereof |
US11179397B2 (en) | 2018-10-03 | 2021-11-23 | Gilead Sciences, Inc. | Imidazopyrimidine derivatives |
WO2021244659A1 (en) | 2020-06-05 | 2021-12-09 | 上海奕拓医药科技有限责任公司 | Isotope-substituted spiro aromatic ring compound and application thereof |
WO2021257736A1 (en) | 2020-06-18 | 2021-12-23 | Revolution Medicines, Inc. | Methods for delaying, preventing, and treating acquired resistance to ras inhibitors |
WO2022060583A1 (en) | 2020-09-03 | 2022-03-24 | Revolution Medicines, Inc. | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
WO2022060836A1 (en) | 2020-09-15 | 2022-03-24 | Revolution Medicines, Inc. | Indole derivatives as ras inhibitors in the treatment of cancer |
WO2022140427A1 (en) | 2020-12-22 | 2022-06-30 | Qilu Regor Therapeutics Inc. | Sos1 inhibitors and uses thereof |
EP4039685A1 (en) | 2021-02-08 | 2022-08-10 | Irbm S.P.A. | Azabicyclic shp2 inhibitors |
EP4067358A1 (en) | 2021-04-02 | 2022-10-05 | C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening | (s)-1-(5-((pyridin-3-yl)thio)pyrazin-2-yl)-4'h,6'h-spiro[piperidine-4,5'-pyrrolo[1,2-b]pyrazol]-4'-amine derivatives and similar compounds as shp2 inhibitors for the treatment of e.g. cancer |
US11466017B2 (en) | 2011-03-10 | 2022-10-11 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of PTPN11 |
US11466016B2 (en) | 2018-03-02 | 2022-10-11 | Otsuka Pharmaceutical Co., Ltd. | Pharmaceutical compounds |
WO2022221304A1 (en) | 2021-04-14 | 2022-10-20 | Gilead Sciences, Inc. | CO-INHIBITION OF CD47/SIRPα BINDING AND NEDD8-ACTIVATING ENZYME E1 REGULATORY SUBUNIT FOR THE TREATMENT OF CANCER |
WO2022235864A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Ras inhibitors |
WO2022235866A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
WO2022235870A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Ras inhibitors for the treatment of cancer |
WO2022245671A1 (en) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Methods of using flt3l-fc fusion proteins |
WO2022259157A1 (en) | 2021-06-09 | 2022-12-15 | Novartis Ag | A triple pharmaceutical combination comprising dabrafenib, trametinib and a shp2 inhibitor |
US11529347B2 (en) | 2016-09-22 | 2022-12-20 | Relay Therapeutics, Inc. | SHP2 phosphatase inhibitors and methods of use thereof |
WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271650A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022269525A1 (en) | 2021-06-23 | 2022-12-29 | Novartis Ag | Pharmaceutical combinations comprising a kras g12c inhibitor and uses thereof for the treatment of cancers |
WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
US11591336B2 (en) | 2017-05-26 | 2023-02-28 | D. E. Shaw Research, Llc | Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors |
WO2023031781A1 (en) | 2021-09-01 | 2023-03-09 | Novartis Ag | Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers |
WO2023060253A1 (en) | 2021-10-08 | 2023-04-13 | Revolution Medicines, Inc. | Ras inhibitors |
US11629145B2 (en) | 2016-10-24 | 2023-04-18 | D. E. Shaw Research, Llc | SHP2 phosphatase inhibitors and methods of use thereof |
WO2023076983A1 (en) | 2021-10-28 | 2023-05-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
WO2023077030A1 (en) | 2021-10-29 | 2023-05-04 | Gilead Sciences, Inc. | Cd73 compounds |
US11673896B2 (en) | 2017-01-23 | 2023-06-13 | Revolution Medicines, Inc. | Pyridine compounds as allosteric SHP2 inhibitors |
RU2797951C2 (en) * | 2018-09-29 | 2023-06-13 | Новартис Аг | Production of compounds and compositions for suppression of shp2 activity |
US11673901B2 (en) | 2017-12-15 | 2023-06-13 | Revolution Medicines, Inc. | Polycyclic compounds as allosteric SHP2 inhibitors |
WO2023107956A1 (en) | 2021-12-08 | 2023-06-15 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and 5t4 |
WO2023107954A1 (en) | 2021-12-08 | 2023-06-15 | Dragonfly Therapeutics, Inc. | Antibodies targeting 5t4 and uses thereof |
WO2023122615A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
WO2023122581A2 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
WO2023122938A1 (en) * | 2021-12-28 | 2023-07-06 | Js Innomed Holdings Ltd. | Heterocyclic compounds as shp2 inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof |
US11702411B2 (en) | 2017-10-12 | 2023-07-18 | Revolution Medicines, Inc. | Pyridine, pyrazine, and triazine compounds as allosteric SHP2 inhibitors |
US11701354B2 (en) | 2017-09-29 | 2023-07-18 | D. E. Shaw Research, Llc | Pyrazolo[3,4-b]pyrazine derivatives as SHP2 phosphatase inhibitors |
WO2023147418A1 (en) | 2022-01-28 | 2023-08-03 | Gilead Sciences, Inc. | Parp7 inhibitors |
US11739093B2 (en) | 2017-01-23 | 2023-08-29 | Revolution Medicines, Inc. | Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors |
WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
EP4245756A1 (en) | 2022-03-17 | 2023-09-20 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
WO2023183817A1 (en) | 2022-03-24 | 2023-09-28 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
WO2023196784A1 (en) | 2022-04-05 | 2023-10-12 | Gilead Sciences, Inc. | Combinations of antibody therapies for treating colorectal cancer |
WO2023205719A1 (en) | 2022-04-21 | 2023-10-26 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
US11827644B2 (en) | 2019-03-04 | 2023-11-28 | Suzhou Genhouse Pharmaceutical Co., Ltd | Pyrazine derivative and application thereof in inhibiting SHP2 |
WO2023230205A1 (en) | 2022-05-25 | 2023-11-30 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
US11890281B2 (en) | 2019-09-24 | 2024-02-06 | Relay Therapeutics, Inc. | SHP2 phosphatase inhibitors and methods of making and using the same |
WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
EP4345101A1 (en) | 2022-09-29 | 2024-04-03 | Irbm S.P.A. | Azole derivatives as shp2 inhibitors |
US11952386B2 (en) | 2014-01-17 | 2024-04-09 | Novartis Ag | N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2 |
WO2024137852A1 (en) | 2022-12-22 | 2024-06-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
US12029739B2 (en) | 2021-07-09 | 2024-07-09 | Kanaph Therapeutics Inc. | SHP2 inhibitor and use thereof |
US12037345B2 (en) | 2018-07-24 | 2024-07-16 | Taiho Pharmaceutical Co., Ltd. | Heterobicyclic compounds for inhibiting the activity of SHP2 |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2021002804A (en) | 2018-12-05 | 2021-07-15 | Mirati Therapeutics Inc | Combination therapies. |
CN111704611B (en) * | 2019-07-25 | 2022-01-14 | 上海凌达生物医药有限公司 | Aryl spiro SHP2 inhibitor compound, preparation method and application |
WO2021043077A1 (en) * | 2019-09-06 | 2021-03-11 | 四川科伦博泰生物医药股份有限公司 | Substituted pyrazine compound and preparation method therefor and use thereof |
CN112724145A (en) * | 2019-10-14 | 2021-04-30 | 杭州雷索药业有限公司 | Pyrazine derivatives for inhibiting SHP2 activity |
CN115279749B (en) * | 2020-04-30 | 2024-05-10 | 贝达药业股份有限公司 | SHP2 inhibitor, composition and application thereof |
AU2022244941B2 (en) * | 2021-03-23 | 2024-08-01 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Heterocycle substituted ketone derivative, and composition and medicinal use thereof |
AU2022274936A1 (en) * | 2021-05-13 | 2023-12-07 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Heterocyclic compound for inhibiting shp2 activity, preparation method therefor and use thereof |
CN113461538A (en) * | 2021-07-12 | 2021-10-01 | 无锡双启科技有限公司 | Preparation method of 2-chloro-3-bromoaniline |
WO2023169170A1 (en) * | 2022-03-10 | 2023-09-14 | 捷思英达控股有限公司 | Heterocyclic compound as shp2 inhibitor, composition comprising heterocyclic compound, and method using same |
WO2024040131A1 (en) | 2022-08-17 | 2024-02-22 | Treeline Biosciences, Inc. | Pyridopyrimidine kras inhibitors |
CN115677660B (en) * | 2022-10-27 | 2024-05-03 | 中国药科大学 | Phenyl urea compound, preparation method, application and pharmaceutical composition thereof |
WO2024147703A1 (en) * | 2023-01-05 | 2024-07-11 | 주식회사 카나프테라퓨틱스 | Shp2 inhibitor and uses thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015107495A1 (en) | 2014-01-17 | 2015-07-23 | Novartis Ag | N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2 |
WO2015107494A1 (en) | 2014-01-17 | 2015-07-23 | Novartis Ag | 1 -(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2 |
WO2015107493A1 (en) | 2014-01-17 | 2015-07-23 | Novartis Ag | 1 -pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2 |
WO2016203406A1 (en) * | 2015-06-19 | 2016-12-22 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
Family Cites Families (170)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3377826B2 (en) | 1993-05-06 | 2003-02-17 | ヘキスト・アクチェンゲゼルシャフト | Novel compounds for use in liquid crystal compositions |
JP2002500618A (en) | 1995-10-31 | 2002-01-08 | イーライ・リリー・アンド・カンパニー | Antithrombotic diamine |
CA2361734A1 (en) | 1999-01-26 | 2000-10-12 | Andre Rosowsky | Pharmaceutically active compounds and methods of use thereof |
US7375125B2 (en) | 1999-08-04 | 2008-05-20 | Ore Pharmaceuticals, Inc. | Melanocortin-4 receptor binding compounds and methods of use thereof |
DE60134679D1 (en) | 2000-10-20 | 2008-08-14 | Eisai R&D Man Co Ltd | Nitrogen-containing aromatic heterocycles |
US20050019424A1 (en) | 2001-12-21 | 2005-01-27 | Adams Paul E. | Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives |
WO2003072548A1 (en) | 2002-02-22 | 2003-09-04 | Pharmacia & Upjohn Company | Pyridyl sulfone derivatives as 5-ht receptor antagonists |
DE10246657A1 (en) | 2002-10-07 | 2004-04-15 | Merck Patent Gmbh | Chiral phenols which induce a cholesteric phase in a nematic liquid crystal and simultaneously act as a stabilizer and are useful in electro-optical displays |
US6939885B2 (en) | 2002-11-18 | 2005-09-06 | Chemocentryx | Aryl sulfonamides |
SE0203712D0 (en) | 2002-12-13 | 2002-12-13 | Astrazeneca Ab | Novel compounds |
ATE402152T1 (en) | 2003-02-07 | 2008-08-15 | Janssen Pharmaceutica Nv | HIV-INHIBITING 1,2,4-TRIAZINE |
US20040248850A1 (en) | 2003-02-11 | 2004-12-09 | Kemia, Inc. | Compounds for the treatment of HIV infection |
GB2400101A (en) | 2003-03-28 | 2004-10-06 | Biofocus Discovery Ltd | Compounds capable of binding to the active site of protein kinases |
WO2004099158A1 (en) | 2003-04-30 | 2004-11-18 | Ricerca Biosciences, Llc. | Monocyclic diazodioxide based bcl-2 protein antagonists |
US7393873B2 (en) | 2003-07-02 | 2008-07-01 | Merck & Co., Inc. | Arylsulfonamide derivatives |
AU2004255920B2 (en) | 2003-07-08 | 2008-05-15 | Astrazeneca Ab | Spiro [1-azabicyclo [2.2.2] octan-3,5'-oxazolidin]-2'-one derivatives with affinity to the alpha7 nicotinic acetylcholine receptor |
MXPA06003615A (en) | 2003-09-30 | 2006-06-05 | Amgen Inc | Vanilloid receptor ligands and their use in treatments. |
GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
TW200528459A (en) | 2004-01-06 | 2005-09-01 | Achillion Pharmaceuticals Inc | Azabenzofuran substituted thioureas; inhibitors of viral replication |
MXPA06007640A (en) | 2004-01-12 | 2007-04-17 | Cytopia Res Pty Ltd | Selective kinase inhibitors. |
CN1950082B (en) | 2004-03-03 | 2013-02-06 | 凯莫森特里克斯股份有限公司 | Bicyclic and bridged nitrogen heterocycles |
US7435831B2 (en) | 2004-03-03 | 2008-10-14 | Chemocentryx, Inc. | Bicyclic and bridged nitrogen heterocycles |
EP1734040A4 (en) * | 2004-03-23 | 2007-11-28 | Banyu Pharma Co Ltd | Substituted quinazoline or pyridopyrimidine derivative |
WO2005108387A2 (en) | 2004-05-03 | 2005-11-17 | Boehringer Ingelheim Pharmaceuticals, Inc. | Cytokine inhibitors |
EA200700117A1 (en) | 2004-06-24 | 2007-06-29 | Инсайт Корпорейшн | N-SUBSTITUTED PIPERIDINES AND THEIR APPLICATION AS PHARMACEUTICAL PREPARATIONS |
US20070043057A1 (en) | 2005-02-09 | 2007-02-22 | Threshold Pharmaceuticals, Inc. | Lonidamine analogs |
ES2508766T3 (en) | 2004-10-29 | 2014-10-16 | Janssen R&D Ireland | Bicyclic pyrimidine derivatives that inhibit HIV |
WO2006063010A2 (en) | 2004-12-08 | 2006-06-15 | Nuada, Llc | Compounds and methods of use thereof |
GB0428082D0 (en) | 2004-12-22 | 2005-01-26 | Welcome Trust The Ltd | Therapeutic compounds |
ES2375395T3 (en) | 2004-12-23 | 2012-02-29 | Mallinckrodt Llc | FLUORESCENT PIRAZINE DERIVATIVES AND METHOD OF USE OF THE SAME IN THE EVALUATION OF RENAL FUNCTION. |
US7622583B2 (en) | 2005-01-14 | 2009-11-24 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2 |
MY158077A (en) | 2005-02-04 | 2016-08-30 | Senomyx Inc | Compounds comprising linked heteroaryl moieties and their use as novel umami flavor modifiers tastants and taste enhancers for comestible compositions |
WO2006087305A1 (en) | 2005-02-16 | 2006-08-24 | Neurosearch A/S | Novel diazabicyclic aryl derivatives and their medical use |
WO2007046867A2 (en) | 2005-05-19 | 2007-04-26 | Xenon Pharmaceuticals Inc. | Piperidine derivatives and their uses as therapeutic agents |
BRPI0610580B8 (en) | 2005-05-30 | 2021-05-25 | Banyu Pharma Co Ltd | piperidine derivative compound |
JP2007013804A (en) | 2005-07-01 | 2007-01-18 | Mitsubishi Electric Corp | Attribute designated communication method and communication apparatus thereof |
WO2007016496A2 (en) * | 2005-08-02 | 2007-02-08 | Neurogen Corporation | Dipiperazinyl ketones and related analogues |
EP1940821B1 (en) | 2005-10-19 | 2013-03-20 | Grünenthal GmbH | Novel vanilloid receptor ligands and their use for producing medicaments |
WO2007057742A2 (en) | 2005-11-18 | 2007-05-24 | Pfizer Products Inc. | Novel piperazinone derivatives |
US20100016319A1 (en) | 2005-11-29 | 2010-01-21 | Toray Industries, Inc. A Corporation Of Japan | Arylmethylene urea derivative and use thereof |
CN101346368A (en) | 2005-12-21 | 2009-01-14 | 詹森药业有限公司 | Substituted pyrazinone derivatives as alpha2c-adrenoreceptor antagonists |
CA2637674A1 (en) | 2006-01-19 | 2007-07-26 | Abbott Laboratories | 2-imino-benzimidazoles |
EP1991544B1 (en) | 2006-01-30 | 2018-08-15 | vTv Therapeutics LLC | Substituted imidazole derivatives and their use as ptpase inhibitors |
RU2008139599A (en) | 2006-03-07 | 2010-04-20 | Эррэй Биофарма Инк. (Us) | Heterobicyclic pyrazole derivatives and methods for their use |
DE602007007206D1 (en) | 2006-04-20 | 2010-07-29 | Janssen Pharmaceutica Nv | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS MEDICAMENTS |
JP2009537602A (en) | 2006-05-22 | 2009-10-29 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Substituted pyrazinone derivatives for use as pharmaceuticals |
PE20081370A1 (en) | 2006-09-11 | 2008-11-28 | Cgi Pharmaceuticals Inc | CERTAIN AMIDAS SUBSTITUTED, METHOD OF PREPARATION AND METHOD OF USE OF THE SAME |
US7838523B2 (en) | 2006-09-11 | 2010-11-23 | Cgi Pharmaceuticals, Inc. | Certain substituted amides, method of making, and method of use thereof |
BRPI0717822A2 (en) | 2006-10-04 | 2013-11-12 | Hoffmann La Roche | COMPOUND, COMPOUND MANUFACTURING PROCESS OF FORMULA I, PHARMACEUTICAL COMPOSITION, METHOD OF TREATMENT AND / OR PROPHYLAXY OF DISEASES WHICH ARE ASSOCIATED WITH THE MODULATION OF CB2 RECEPTORS AND USE OF COMPOUND. |
DE102007018150A1 (en) | 2007-04-16 | 2008-10-23 | Grünenthal GmbH | Treating pain, using dual action compound or combination of compounds with affinity for both mu-opioid and vanilloid VR1-receptors, also effective e.g. against coughs or asthma |
EP2120573A4 (en) | 2007-02-12 | 2011-05-25 | Merck Sharp & Dohme | Piperidine derivatives |
US8338437B2 (en) | 2007-02-28 | 2012-12-25 | Methylgene Inc. | Amines as small molecule inhibitors |
EP2131861A2 (en) | 2007-03-01 | 2009-12-16 | Mallinckrodt Inc. | Integrated photoactive small molecules and uses thereof |
EP2132177B1 (en) | 2007-03-01 | 2013-07-17 | Novartis AG | Pim kinase inhibitors and methods of their use |
WO2008112674A1 (en) | 2007-03-12 | 2008-09-18 | Irm Llc | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity |
CN101918403A (en) | 2007-09-06 | 2010-12-15 | 阵列生物制药公司 | Pyrazolo-pyridines as tyrosine kinase inhibitor |
WO2009036066A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Vegfr inhibitors containing a zinc binding moiety |
EP2197873B1 (en) | 2007-09-20 | 2014-07-16 | Irm Llc | Compounds and compositions as modulators of gpr119 activity |
NZ585347A (en) | 2007-10-18 | 2011-09-30 | Boehringer Ingelheim Int | Cgrp antagonists |
JP2011500807A (en) | 2007-10-24 | 2011-01-06 | メルク・シャープ・エンド・ドーム・コーポレイション | Pyrazinylamide T-type calcium channel antagonist |
US20110027264A1 (en) | 2008-02-29 | 2011-02-03 | Xianhai Huang | Gamma secretase modulators for the treatment of alzheimer's disease |
CA2719538C (en) | 2008-04-07 | 2014-03-18 | Amgen Inc. | Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors |
CL2009001064A1 (en) | 2008-05-07 | 2009-10-09 | Galapagos Nv | Compounds derived from fused imidazole pyrazine or triazole pyrazine, mapkapk5 inhibitors; pharmaceutical composition comprising said compounds; and use to prepare a medicament for the treatment of inflammation, especially rheumatoid arthritis. |
EP2328586A2 (en) | 2008-05-20 | 2011-06-08 | Cephalon, Inc. | Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands |
JP2011524917A (en) | 2008-06-20 | 2011-09-08 | メタボレックス, インコーポレイテッド | Aryl GPR119 agonists and uses thereof |
GEP20135785B (en) | 2008-08-22 | 2013-03-11 | Novartis Ag | Pyrrolopyrimidine compounds as cdk inhibitors |
CA2738429C (en) | 2008-09-26 | 2016-10-25 | Intellikine, Inc. | Heterocyclic kinase inhibitors |
ES2397934T3 (en) | 2008-12-17 | 2013-03-12 | Amgen Inc. | Aminopyridine and carboxypyridine compounds as phosphodiesterase 10 inhibitors |
US8952014B2 (en) | 2008-12-19 | 2015-02-10 | Boehringer Ingelheim International Gmbh | Pyrimidine derivatives which are CGRP—antagonists |
MY150774A (en) | 2008-12-25 | 2014-02-28 | Taisho Pharmaceutical Co Ltd | Isoquinoline derivative |
DK2389388T3 (en) | 2009-01-22 | 2017-05-01 | Keybioscience Ag | TREATMENT FOR Obesity |
WO2010086613A1 (en) | 2009-01-30 | 2010-08-05 | Betagenon Ab | Compounds useful as inhibitors as ampk |
JP5765239B2 (en) | 2009-03-13 | 2015-08-19 | アドヴィナス・セラピューティックス・リミテッド | Substituted fused pyrimidine compounds |
EP2451794B1 (en) | 2009-07-08 | 2016-01-27 | Baltic Bio Ab | 1,2,4-thiazolidin-3-one derivatives and their use in the treatment of cancer |
EP3205647B1 (en) | 2009-08-17 | 2020-05-13 | Memorial Sloan-Kettering Cancer Center | 2-(pyrimidin-5-yl)-thiopyrimidine derivatives as hsp70 and hsc70 modulators for the treatment of proliferative disorders |
EP2473500A2 (en) | 2009-09-01 | 2012-07-11 | Pfizer Inc. | Benzimidazole derivatives |
CN102686579A (en) | 2009-10-09 | 2012-09-19 | Irm责任有限公司 | Compounds and compositions as modulators of GPR119 activity |
US8759377B2 (en) | 2009-11-23 | 2014-06-24 | Vanderbilt University | Substituted dioxopiperidines and dioxopyrrolidines as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
BR112012014164A2 (en) | 2009-12-14 | 2016-05-17 | Merck Patent Gmbh | sphingosine kinase inhibitors |
WO2011075607A1 (en) | 2009-12-18 | 2011-06-23 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
EP2536283B8 (en) | 2010-02-18 | 2015-11-04 | vTv Therapeutics LLC | Phenyl-heteroaryl derivatives and methods of use thereof |
EP2558092B1 (en) | 2010-04-13 | 2018-06-27 | Novartis AG | Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase 6 (cdk4/6) inhibitor and an mtor inhibitor for treating cancer |
EP2563780B1 (en) | 2010-04-29 | 2015-05-06 | The University Of Edinburgh | 3,3-disubstituted-(8-aza-bicyclo[3.2.1]oct-8-yl)-[5-(1h-pyrazol-4-yl)-thiophen-3-yl]-methanones as inhibitors of 11(beta)-hsd1 |
US20110312996A1 (en) | 2010-05-17 | 2011-12-22 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
EP2576540B1 (en) | 2010-05-26 | 2019-09-04 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
MX338707B (en) | 2010-07-29 | 2016-04-28 | Rigel Pharmaceuticals Inc | Ampk-activating heterocyclic compounds and methods for using the same. |
JP2013230986A (en) | 2010-08-25 | 2013-11-14 | Kyorin Pharmaceutical Co Ltd | Novel hydantoin derivative and medicinal agent comprising the same as active ingredient |
CN102432598A (en) | 2010-09-29 | 2012-05-02 | 江苏恒瑞医药股份有限公司 | Tricyclic compound, preparation method thereof and pharmaceutical application thereof |
WO2012068106A2 (en) * | 2010-11-15 | 2012-05-24 | Exelixis, Inc. | Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture |
GB201020161D0 (en) | 2010-11-26 | 2011-01-12 | Almac Discovery Ltd | Pharmaceutical compounds |
ES2650744T3 (en) | 2010-12-14 | 2018-01-22 | Electrophoretics Limited | Casein kinase 1 delta inhibitors (CK1delta) |
EP2655334B1 (en) | 2010-12-22 | 2018-10-03 | Eutropics Pharmaceuticals, Inc. | Compositions and methods useful for treating diseases |
US20120184572A1 (en) | 2011-01-13 | 2012-07-19 | Metabolex, Inc. | Aryl gpr119 agonists and uses thereof |
MX2013012588A (en) | 2011-04-29 | 2014-05-20 | Icahn School Med Mount Sinai | Kinase inhibitors. |
US9586928B2 (en) | 2011-05-16 | 2017-03-07 | The Scripps Research Institute | Modulators of the nuclear hormone receptor ROR |
US20120316182A1 (en) * | 2011-06-10 | 2012-12-13 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
EP2554544A1 (en) | 2011-08-01 | 2013-02-06 | Almirall, S.A. | Pyridin-2(1h)-one derivatives as jak inhibitors |
WO2013039851A1 (en) | 2011-09-12 | 2013-03-21 | Mallinckrodt Llc | Optical agents for imaging and visualization of matrix metalloproteinase enzymes |
CN104080767A (en) | 2011-12-12 | 2014-10-01 | 瑞塞普托斯公司 | Novel GLP-1 receptor modulators |
CN112029513B (en) | 2012-02-22 | 2024-02-23 | 默克专利股份有限公司 | Liquid-crystalline medium |
GB201204985D0 (en) | 2012-03-21 | 2012-05-02 | Genentech Inc | Compounds |
US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
JP6175673B2 (en) | 2012-04-25 | 2017-08-09 | ラクオリア創薬株式会社 | Amide derivatives as TTX-S blockers |
BR112014027133A2 (en) | 2012-05-09 | 2017-06-27 | Basf Se | compound, agricultural or veterinary composition, method for controlling invertebrate pests, plant propagating material and method for treating or protecting an animal. |
WO2014000178A1 (en) | 2012-06-27 | 2014-01-03 | Merck Sharp & Dohme Corp. | Sulfonamide derivatives and methods of use thereof for improving the pharmacokinetics of a drug |
JP6242885B2 (en) | 2012-06-27 | 2017-12-06 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 5-azaindazole compounds and methods of use |
CA2882132C (en) | 2012-08-16 | 2021-07-06 | The Scripps Research Institute | Kappa opioid ligands |
JOP20130273B1 (en) | 2012-09-11 | 2021-08-17 | Genzyme Corp | Glucosylceramide synthase inhibitors |
AU2013341115B2 (en) * | 2012-11-09 | 2016-07-14 | Glaxosmithkline Llc | Novel compounds as diacylglycerol acyltransferase inhibitors |
LT2968290T (en) | 2013-03-15 | 2019-12-10 | G1 Therapeutics Inc | Transient protection of normal cells during chemotherapy |
KR20150128863A (en) | 2013-03-15 | 2015-11-18 | 에프. 호프만-라 로슈 아게 | ARYL SULFAMIDE AND SULFAMATE DERIVATIVES AS RORc MODULATORS |
WO2014184074A1 (en) | 2013-05-15 | 2014-11-20 | Basf Se | Substituted n-(tetrazol-5-yl)- and n-(triazol-5-yl)hetarylcarboxamide compounds and their use as herbicides |
WO2014184014A1 (en) | 2013-05-15 | 2014-11-20 | Basf Se | N-(1,2,5-oxadiazol-3-yl)carboxamide compounds and their use as herbicides |
GB201309508D0 (en) | 2013-05-28 | 2013-07-10 | Redx Pharma Ltd | Compounds |
AU2014278183B2 (en) | 2013-06-11 | 2018-10-04 | Receptos Llc | Novel GLP-1 receptor modulators |
CA2953482A1 (en) | 2013-07-03 | 2015-01-08 | Indiana University Research & Technology Corporation | Shp2 inhibitors and methods of treating autoimmune and/or glomerulonephritis-associated diseases using shp2 inhibitors |
CN104341386A (en) * | 2013-07-23 | 2015-02-11 | 中国科学院上海药物研究所 | Aryl heterocycle micromolecule compounds, derivatives thereof, and preparing methods and uses of the compounds and the derivatives |
US20160159773A1 (en) | 2013-07-30 | 2016-06-09 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
US9751881B2 (en) | 2013-07-31 | 2017-09-05 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
US20150087673A1 (en) | 2013-09-26 | 2015-03-26 | Rigel Pharmaceuticals, Inc. | Methods for using and biomarkers for ampk-activating compounds |
EP3055287B1 (en) | 2013-10-08 | 2019-11-06 | Lu, Qing-Bin | Non-platinum-based anti-cancer compounds for use in targeted chemotherapy |
WO2015061247A2 (en) | 2013-10-21 | 2015-04-30 | Merck Patent Gmbh | Heteroaryl compounds as btk inhibitors and uses thereof |
KR20150070027A (en) | 2013-12-16 | 2015-06-24 | 메르크 파텐트 게엠베하 | Liquid-crystalline medium |
US9624199B2 (en) | 2013-12-19 | 2017-04-18 | Bayer Pharma Aktiengesellschaft | Substituted bipiperidinyl derivatives |
US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
WO2015123533A1 (en) | 2014-02-14 | 2015-08-20 | Takeda Pharmaceutical Company Limited | Pyrazines modulators of gpr6 |
WO2015148714A1 (en) | 2014-03-25 | 2015-10-01 | Duke University | Heat shock protein 70 (hsp-70) receptor ligands |
MX368767B (en) | 2014-04-07 | 2019-10-15 | Netherlands Translational Res Center B V | (5,6-dihydro)pyrimido[4,5-e]indolizines. |
CN106458991A (en) | 2014-05-23 | 2017-02-22 | 豪夫迈·罗氏有限公司 | Benzene sulfonamide derivatives and their use as RORC modulators |
CN105294683B (en) | 2014-07-26 | 2018-01-23 | 广东东阳光药业有限公司 | Compound of CDK type small molecular inhibitors and application thereof |
WO2016022645A1 (en) | 2014-08-06 | 2016-02-11 | Merck Sharp & Dohme Corp. | Heterocyclic cgrp receptor antagonists |
WO2016022644A1 (en) | 2014-08-06 | 2016-02-11 | Merck Sharp & Dohme Corp. | Heterocyclic cgrp receptor antagonists |
EP2985334B1 (en) | 2014-08-15 | 2018-06-20 | Merck Patent GmbH | Liquid-crystalline medium |
WO2016037005A1 (en) * | 2014-09-05 | 2016-03-10 | Quanticel Pharmaceuticals, Inc. | Inhibitors of lysine specific demethylase-1 |
WO2016040449A1 (en) | 2014-09-10 | 2016-03-17 | Raze Therapeutics, Inc. | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof |
EP3262049B1 (en) | 2015-02-27 | 2022-07-20 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
CN107428731B (en) | 2015-03-11 | 2020-05-05 | 正大天晴药业集团股份有限公司 | Substituted 2-hydro-pyrazole derivatives as anti-cancer agents |
CN107787226A (en) | 2015-03-25 | 2018-03-09 | 诺华股份有限公司 | Drug regimen |
TWI703150B (en) | 2015-06-04 | 2020-09-01 | 美商庫拉腫瘤技術股份有限公司 | Methods and compositions for inhibiting the interaction of menin and mll proteins |
US10588907B2 (en) | 2015-06-04 | 2020-03-17 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
ES2824576T3 (en) * | 2015-06-19 | 2021-05-12 | Novartis Ag | Compounds and compositions to inhibit SHP2 activity |
ES2741746T3 (en) | 2015-06-19 | 2020-02-12 | Novartis Ag | Compounds and compositions to inhibit SHP2 activity |
RU2604047C1 (en) | 2015-07-10 | 2016-12-10 | Фортис Аксис, Закрытое Акционерное Общество | Masseur for back muscles exercising three vertebral parts |
EP3328382A4 (en) | 2015-09-17 | 2018-12-19 | Marvin J. Miller | Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection |
WO2017114351A1 (en) | 2015-12-27 | 2017-07-06 | Chongqing Fochon Pharmaceutical Co., Ltd. | Certain protein kinase inhibitors |
WO2017156397A1 (en) | 2016-03-11 | 2017-09-14 | Board Of Regents, The University Of Texas Sysytem | Heterocyclic inhibitors of ptpn11 |
EP3434676B1 (en) | 2016-03-25 | 2022-03-09 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Substituted pyrrolopyrimidine cdk inhibitor, pharmaceutical composition containing same and use thereof |
CN107286150B (en) | 2016-04-11 | 2020-07-07 | 中国科学院上海有机化学研究所 | N-heterocyclic compound, intermediate thereof, preparation method, pharmaceutical composition and application |
AU2017274199B2 (en) | 2016-05-31 | 2021-09-23 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of PTPN11 |
WO2017211303A1 (en) * | 2016-06-07 | 2017-12-14 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as shp2 inhibitors |
KR102457146B1 (en) | 2016-06-14 | 2022-10-19 | 노파르티스 아게 | Compounds and compositions for inhibiting the activity of SHP2 |
IL311645A (en) | 2016-07-12 | 2024-05-01 | Revolution Medicines Inc | 2,5- disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines asallosteric shp2 inhibitors |
EP3290412A1 (en) | 2016-08-31 | 2018-03-07 | Università degli Studi di Siena | Hiv-1 nucleocapsid inhibitors |
US11529347B2 (en) | 2016-09-22 | 2022-12-20 | Relay Therapeutics, Inc. | SHP2 phosphatase inhibitors and methods of use thereof |
WO2018089433A1 (en) | 2016-11-08 | 2018-05-17 | Navitor Pharmaceuticals, Inc. | PHENYL mTORC INHIBITORS AND USES THEREOF |
EP3565810A1 (en) | 2017-01-03 | 2019-11-13 | ViiV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
KR102571130B1 (en) * | 2017-01-10 | 2023-08-28 | 노파르티스 아게 | A pharmaceutical combination comprising an ALK inhibitor and a SHP2 inhibitor |
JP2020504164A (en) * | 2017-01-25 | 2020-02-06 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation | Prevention and treatment of acute myeloid leukemia |
US10988466B2 (en) * | 2017-03-23 | 2021-04-27 | Jacobio Pharmaceuticals Co., Ltd. | Heterocyclic derivatives useful as SHP2 inhibitors |
CN109803972B (en) | 2017-04-01 | 2021-11-23 | 晟科药业(江苏)有限公司 | 1H-imidazole [4,5-H ] quinazoline compound as protein kinase inhibitor |
AU2018300980A1 (en) | 2017-07-12 | 2020-01-02 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
JP2020536881A (en) | 2017-10-12 | 2020-12-17 | レヴォリューション・メディスンズ,インコーポレイテッド | Pyridine, pyrazine and triazine compounds as allosteric SHP2 inhibitors |
IL273924B2 (en) | 2017-10-20 | 2024-07-01 | Univ Vanderbilt | Antagonists of the muscarinic acetylcholine receptor m4 |
CA3080941A1 (en) | 2017-12-22 | 2019-06-27 | Dana-Farber Cancer Institute, Inc. | Nek inhibitors and methods of use |
TW201940481A (en) | 2018-01-29 | 2019-10-16 | 美商維泰克斯製藥公司 | GCN2 inhibitors and uses thereof |
IL301089A (en) | 2018-01-29 | 2023-05-01 | Vertex Pharma | Gcn2 inhibitors and uses thereof |
US11426422B2 (en) | 2018-01-30 | 2022-08-30 | Research Development Foundation | SHP2 inhibitors and methods of use thereof |
CN111954668A (en) | 2018-02-08 | 2020-11-17 | 埃尼奥制药公司 | Fused thiophene derivative and use thereof |
CN111902415A (en) | 2018-03-02 | 2020-11-06 | 大冢制药株式会社 | Pharmaceutical compounds |
CN111936144B (en) | 2018-03-21 | 2023-12-22 | 廖细斌 | JAK inhibitors |
-
2017
- 2017-06-07 WO PCT/CN2017/087471 patent/WO2017211303A1/en unknown
- 2017-06-07 EP EP17809742.4A patent/EP3464272B1/en active Active
- 2017-06-07 EA EA201990001A patent/EA201990001A1/en unknown
- 2017-06-07 SI SI201731100T patent/SI3464272T1/en unknown
- 2017-06-07 KR KR1020217037106A patent/KR20210141778A/en not_active Application Discontinuation
- 2017-06-07 CN CN201780035294.3A patent/CN109311848B/en active Active
- 2017-06-07 KR KR1020237022188A patent/KR20230109185A/en not_active Application Discontinuation
- 2017-06-07 HR HRP20220251TT patent/HRP20220251T1/en unknown
- 2017-06-07 DK DK17809742.4T patent/DK3464272T3/en active
- 2017-06-07 EA EA202092441A patent/EA202092441A1/en unknown
- 2017-06-07 JP JP2019517133A patent/JP6751203B2/en active Active
- 2017-06-07 SG SG11201810983PA patent/SG11201810983PA/en unknown
- 2017-06-07 CN CN202011246514.7A patent/CN112250670B/en active Active
- 2017-06-07 CN CN202210183947.5A patent/CN114539273A/en active Pending
- 2017-06-07 US US16/307,827 patent/US10858359B2/en active Active
- 2017-06-07 MX MX2018015297A patent/MX2018015297A/en unknown
- 2017-06-07 CA CA3026784A patent/CA3026784A1/en active Pending
- 2017-06-07 KR KR1020227029335A patent/KR20220124275A/en not_active Application Discontinuation
- 2017-06-07 SG SG10202110874TA patent/SG10202110874TA/en unknown
- 2017-06-07 PL PL17809742T patent/PL3464272T3/en unknown
- 2017-06-07 AU AU2017276457A patent/AU2017276457B2/en active Active
- 2017-06-07 RS RS20220205A patent/RS62987B1/en unknown
- 2017-06-07 ES ES17809742T patent/ES2908801T3/en active Active
- 2017-06-07 HU HUE17809742A patent/HUE057838T2/en unknown
- 2017-06-07 KR KR1020217004404A patent/KR20210019607A/en not_active Application Discontinuation
- 2017-06-07 LT LTEPPCT/CN2017/087471T patent/LT3464272T/en unknown
- 2017-06-07 EA EA202092442A patent/EA202092442A3/en unknown
- 2017-06-07 PT PT178097424T patent/PT3464272T/en unknown
- 2017-06-07 EP EP21212393.9A patent/EP4108659A1/en active Pending
- 2017-06-07 MA MA045189A patent/MA45189A/en unknown
- 2017-06-07 KR KR1020197000391A patent/KR102218333B1/en active IP Right Grant
-
2018
- 2018-12-07 PH PH12018550202A patent/PH12018550202A1/en unknown
- 2018-12-07 MX MX2021015073A patent/MX2021015073A/en unknown
- 2018-12-07 MX MX2021015074A patent/MX2021015074A/en unknown
-
2020
- 2020-08-13 JP JP2020136588A patent/JP2020189868A/en active Pending
-
2022
- 2022-03-02 CY CY20221100180T patent/CY1125042T1/en unknown
- 2022-08-03 JP JP2022123777A patent/JP2022153616A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015107495A1 (en) | 2014-01-17 | 2015-07-23 | Novartis Ag | N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2 |
WO2015107494A1 (en) | 2014-01-17 | 2015-07-23 | Novartis Ag | 1 -(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2 |
WO2015107493A1 (en) | 2014-01-17 | 2015-07-23 | Novartis Ag | 1 -pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2 |
WO2016203406A1 (en) * | 2015-06-19 | 2016-12-22 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
Non-Patent Citations (2)
Title |
---|
"Design of Prodrugs", 1985, ELSEVIER |
"REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY", 1995, MACK PUBLISHING CO. |
Cited By (175)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11466017B2 (en) | 2011-03-10 | 2022-10-11 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of PTPN11 |
US11952386B2 (en) | 2014-01-17 | 2024-04-09 | Novartis Ag | N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2 |
US11840536B2 (en) | 2016-05-31 | 2023-12-12 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of PTPN11 |
US10851110B2 (en) | 2016-05-31 | 2020-12-01 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of PTPN11 |
US10858359B2 (en) | 2016-06-07 | 2020-12-08 | Jacobio Pharmaceuticals Co., Ltd. | Heterocyclic ring derivatives useful as SHP2 inhibitors |
US11905283B2 (en) | 2016-06-14 | 2024-02-20 | Novartis Ag | Compounds and compositions for inhibiting the activity of SHP2 |
JP2022037083A (en) * | 2016-06-14 | 2022-03-08 | ノバルティス アーゲー | Compound and composition for inhibiting activity of shp2 |
US10934285B2 (en) | 2016-06-14 | 2021-03-02 | Novartis Ag | Compounds and compositions for inhibiting the activity of SHP2 |
JP7278359B2 (en) | 2016-06-14 | 2023-05-19 | ノバルティス アーゲー | Compounds and compositions for inhibiting the activity of SHP2 |
US10590090B2 (en) | 2016-07-12 | 2020-03-17 | Revolution Medicines, Inc. | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors |
US11661401B2 (en) | 2016-07-12 | 2023-05-30 | Revolution Medicines, Inc. | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors |
EP4302834A3 (en) * | 2016-07-12 | 2024-07-17 | Revolution Medicines, Inc. | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors |
US11529347B2 (en) | 2016-09-22 | 2022-12-20 | Relay Therapeutics, Inc. | SHP2 phosphatase inhibitors and methods of use thereof |
US11629145B2 (en) | 2016-10-24 | 2023-04-18 | D. E. Shaw Research, Llc | SHP2 phosphatase inhibitors and methods of use thereof |
US11739093B2 (en) | 2017-01-23 | 2023-08-29 | Revolution Medicines, Inc. | Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors |
US11673896B2 (en) | 2017-01-23 | 2023-06-13 | Revolution Medicines, Inc. | Pyridine compounds as allosteric SHP2 inhibitors |
AU2018239542B2 (en) * | 2017-03-23 | 2020-08-20 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as SHP2 inhibitors |
EP3601239A4 (en) * | 2017-03-23 | 2020-05-13 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as shp2 inhibitors |
EP3601239B1 (en) * | 2017-03-23 | 2024-07-31 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as shp2 inhibitors |
US10988466B2 (en) | 2017-03-23 | 2021-04-27 | Jacobio Pharmaceuticals Co., Ltd. | Heterocyclic derivatives useful as SHP2 inhibitors |
AU2022204681B2 (en) * | 2017-03-23 | 2024-02-22 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as SHP2 inhibitors |
WO2018172984A1 (en) | 2017-03-23 | 2018-09-27 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as shp2 inhibitors |
AU2018239542C1 (en) * | 2017-03-23 | 2021-02-11 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as SHP2 inhibitors |
US11591336B2 (en) | 2017-05-26 | 2023-02-28 | D. E. Shaw Research, Llc | Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors |
US11596633B2 (en) | 2017-09-07 | 2023-03-07 | Revolution Medicines, Inc. | SHP2 inhibitor compositions and methods for treating cancer |
WO2019051084A1 (en) | 2017-09-07 | 2019-03-14 | Revolution Medicines, Inc. | Shp2 inhibitor compositions and methods for treating cancer |
US10435389B2 (en) | 2017-09-11 | 2019-10-08 | Krouzon Pharmaccuticals, Inc. | Octahydrocyclopenta[c]pyrrole allosteric inhibitors of SHP2 |
US11701354B2 (en) | 2017-09-29 | 2023-07-18 | D. E. Shaw Research, Llc | Pyrazolo[3,4-b]pyrazine derivatives as SHP2 phosphatase inhibitors |
US11702411B2 (en) | 2017-10-12 | 2023-07-18 | Revolution Medicines, Inc. | Pyridine, pyrazine, and triazine compounds as allosteric SHP2 inhibitors |
US11673901B2 (en) | 2017-12-15 | 2023-06-13 | Revolution Medicines, Inc. | Polycyclic compounds as allosteric SHP2 inhibitors |
US11498930B2 (en) | 2018-02-13 | 2022-11-15 | Blueray Therapeutics (Shanghai) Co., Ltd | Pyrimidine-fused cyclic compound, preparation method therefor and application thereof |
WO2019158019A1 (en) | 2018-02-13 | 2019-08-22 | 上海青煜医药科技有限公司 | Pyrimidine-fused cyclic compound, preparation method therefor and application thereof |
US11466016B2 (en) | 2018-03-02 | 2022-10-11 | Otsuka Pharmaceutical Co., Ltd. | Pharmaceutical compounds |
JP2021518441A (en) * | 2018-03-21 | 2021-08-02 | リレー セラピューティクス, インコーポレイテッド | SHP2 phosphatase inhibitors and how to use them |
JP7418395B2 (en) | 2018-03-21 | 2024-01-19 | リレー セラピューティクス, インコーポレイテッド | SHP2 phosphatase inhibitors and methods of using them |
IL277434B1 (en) * | 2018-03-21 | 2023-04-01 | Relay Therapeutics Inc | Shp2 phosphatase inhibitors and methods of use thereof |
CN112166110B (en) * | 2018-03-21 | 2023-08-11 | 传达治疗有限公司 | SHP2 phosphatase inhibitors and methods of use thereof |
CN112166110A (en) * | 2018-03-21 | 2021-01-01 | 传达治疗有限公司 | SHP2 phosphatase inhibitors and methods of use thereof |
US10561655B2 (en) | 2018-03-21 | 2020-02-18 | Synblia Therapeutics, Inc. | SHP2 inhibitors and uses thereof |
WO2019183367A1 (en) * | 2018-03-21 | 2019-09-26 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
US10934302B1 (en) | 2018-03-21 | 2021-03-02 | Relay Therapeutics, Inc. | SHP2 phosphatase inhibitors and methods of use thereof |
US12084447B2 (en) | 2018-03-21 | 2024-09-10 | Relay Therapeutics, Inc. | SHP2 phosphatase inhibitors and methods of use thereof |
WO2019199792A1 (en) | 2018-04-10 | 2019-10-17 | Revolution Medicines, Inc. | Shp2 inhibitor compositions, methods for treating cancer and methods for identifying a subject with shp2 mutations |
US10954243B2 (en) | 2018-05-02 | 2021-03-23 | Navire Pharma, Inc. | Substituted heterocyclic inhibitors of PTPN11 |
US11932643B2 (en) | 2018-05-02 | 2024-03-19 | Navire Pharma, Inc. | Substituted heterocyclic inhibitors of PTPN11 |
CN110143949A (en) * | 2018-05-09 | 2019-08-20 | 北京加科思新药研发有限公司 | It can be used as the new type heterocycle derivative of SHP2 inhibitor |
CN115721648A (en) * | 2018-05-09 | 2023-03-03 | 北京加科思新药研发有限公司 | Novel heterocyclic derivatives useful as SHP2 inhibitors |
CN115969853A (en) * | 2018-05-09 | 2023-04-18 | 北京加科思新药研发有限公司 | Novel heterocyclic derivatives useful as SHP2 inhibitors |
CN112409334B (en) * | 2018-05-09 | 2022-12-02 | 北京加科思新药研发有限公司 | Heterocyclic derivatives useful as SHP2 inhibitors |
CN112409334A (en) * | 2018-05-09 | 2021-02-26 | 北京加科思新药研发有限公司 | Novel heterocyclic derivatives useful as SHP2 inhibitors |
CN112174935B (en) * | 2018-05-09 | 2022-12-06 | 北京加科思新药研发有限公司 | Heterocyclic derivatives useful as SHP2 inhibitors |
CN112174935A (en) * | 2018-05-09 | 2021-01-05 | 北京加科思新药研发有限公司 | Novel heterocyclic derivatives useful as SHP2 inhibitors |
US12037345B2 (en) | 2018-07-24 | 2024-07-16 | Taiho Pharmaceutical Co., Ltd. | Heterobicyclic compounds for inhibiting the activity of SHP2 |
US11104675B2 (en) | 2018-08-10 | 2021-08-31 | Navire Pharma, Inc. | PTPN11 inhibitors |
US11945815B2 (en) | 2018-08-10 | 2024-04-02 | Navire Pharma, Inc. | PTPN11 inhibitors |
JP2021534124A (en) * | 2018-08-10 | 2021-12-09 | ナビール ファーマ,インコーポレイティド | 6- (4-Amino-3-methyl-2-oxa-8-azaspiro [4.5] decane-8-yl) -3- (2,3-dichlorophenyl) as an inhibitor of PTPN11 (SHP2) for the treatment of cancer -2-Methylpyrimidine-4 (3H) -one derivative and related compounds |
US10894797B2 (en) | 2018-09-18 | 2021-01-19 | Nikang Therapeutics, Inc. | Fused tricyclic ring derivatives as SRC homology-2 phosphatase inhibitors |
JP7337174B2 (en) | 2018-09-18 | 2023-09-01 | ニカング セラピューティクス, インコーポレイテッド | Trisubstituted Heteroaryl Derivatives as Src Homology-2 Phosphatase Inhibitors |
US11459340B2 (en) | 2018-09-18 | 2022-10-04 | Nikang Therapeutics, Inc. | Tri-substituted heteroaryl derivatives as Src homology-2 phosphatase inhibitors |
CN113227103A (en) * | 2018-09-18 | 2021-08-06 | 尼坎医疗公司 | Trisubstituted heteroaryl derivatives as SRC homologous-2 phosphatase inhibitors |
JP2022501430A (en) * | 2018-09-18 | 2022-01-06 | ニカング セラピューティクス, インコーポレイテッド | Tri-substituted heteroaryl derivative as Src homology-2 phosphatase inhibitor |
AU2019344897B2 (en) * | 2018-09-18 | 2024-01-18 | Nikang Therapeutics, Inc. | Tri-substituted heteroaryl derivatives AS SRC homology-2 phosphatase inhibitors |
WO2020061101A1 (en) * | 2018-09-18 | 2020-03-26 | Nikang Therapeutics, Inc. | Tri-substituted heteroaryl derivatives as src homology-2 phosphatase inhibitors |
US11518772B2 (en) | 2018-09-18 | 2022-12-06 | Nikang Therapeutics, Inc. | Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors |
US11034705B2 (en) | 2018-09-18 | 2021-06-15 | Nikang Therapeutics, Inc. | Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors |
WO2020063760A1 (en) * | 2018-09-26 | 2020-04-02 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as shp2 inhibitors |
WO2020065453A1 (en) * | 2018-09-29 | 2020-04-02 | Novartis Ag | Process of manufacture of a compound for inhibiting the activity of shp2 |
TWI829771B (en) * | 2018-09-29 | 2024-01-21 | 瑞士商諾華公司 | Manufacture of compounds and compositions for inhibiting the activity of shp2 |
CN112867718A (en) * | 2018-09-29 | 2021-05-28 | 诺华股份有限公司 | Manufacture of Compounds and compositions for inhibiting SHP2 Activity |
JP2022502385A (en) * | 2018-09-29 | 2022-01-11 | ノバルティス アーゲー | Method for producing a compound for inhibiting the activity of SHP2 |
WO2020065452A1 (en) * | 2018-09-29 | 2020-04-02 | Novartis Ag | Manufacture of compounds and compositions for inhibiting the activity of shp2 |
TWI844568B (en) * | 2018-09-29 | 2024-06-11 | 瑞士商諾華公司 | Process of manufacture of a compound for inhibiting the activity of shp2, as well as products resulting from acid addition |
US11873307B2 (en) | 2018-09-29 | 2024-01-16 | Novartis Ag | Manufacture of compounds and compositions for inhibiting the activity of SHP2 |
IL281726B2 (en) * | 2018-09-29 | 2024-03-01 | Novartis Ag | Manufacture of compounds and compositions for inhibiting the activity of shp2 |
RU2797951C2 (en) * | 2018-09-29 | 2023-06-13 | Новартис Аг | Production of compounds and compositions for suppression of shp2 activity |
IL281726B1 (en) * | 2018-09-29 | 2023-11-01 | Novartis Ag | Manufacture of compounds and compositions for inhibiting the activity of shp2 |
US11179397B2 (en) | 2018-10-03 | 2021-11-23 | Gilead Sciences, Inc. | Imidazopyrimidine derivatives |
WO2020076723A1 (en) | 2018-10-08 | 2020-04-16 | Revolution Medicines, Inc. | Shp2 inhibitor compositions for use in treating cancer |
WO2020073949A1 (en) * | 2018-10-10 | 2020-04-16 | 江苏豪森药业集团有限公司 | Regulator of nitrogen-containing heteroaromatic derivatives, preparation method therefor and use thereof |
EP3868742A4 (en) * | 2018-10-10 | 2022-11-23 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Regulator of nitrogen-containing heteroaromatic derivatives, preparation method therefor and use thereof |
CN111295374A (en) * | 2018-10-10 | 2020-06-16 | 江苏豪森药业集团有限公司 | Aza-containing aromatic derivative regulator, preparation method and application thereof |
CN115353509A (en) * | 2018-10-10 | 2022-11-18 | 江苏豪森药业集团有限公司 | Aza-containing aromatic derivative regulator, preparation method and application thereof |
JP2022504352A (en) * | 2018-10-10 | 2022-01-13 | ジエンス ハンセン ファーマセウティカル グループ カンパニー リミテッド | Control factors for nitrogen-containing heteroaromatic derivatives, their production methods and uses |
CN115353509B (en) * | 2018-10-10 | 2024-04-12 | 江苏豪森药业集团有限公司 | Nitrogen-containing heteroaromatic derivative regulator, preparation method and application thereof |
CN111295374B (en) * | 2018-10-10 | 2022-11-04 | 江苏豪森药业集团有限公司 | Aza-containing aromatic derivative regulator, preparation method and application thereof |
WO2020081848A1 (en) | 2018-10-17 | 2020-04-23 | Array Biopharma Inc. | Protein tyrosine phosphatase inhibitors |
CN111138412B (en) * | 2018-11-06 | 2023-09-15 | 上海奕拓医药科技有限责任公司 | Spiro aromatic ring compound and application thereof |
EP4074713A1 (en) | 2018-11-06 | 2022-10-19 | Etern Biopharma (Shanghai) Co., Ltd. | 1'-(imidazo[1,2-c]pyrimidin-5-yl)-5,7-dihydrospiro[cyclopenta[b]pyridine-6,4'-piperidine]-5-amine derivatives and related compounds as shp2 inhibitors for the treatment of cancer |
CN111138412A (en) * | 2018-11-06 | 2020-05-12 | 上海奕拓医药科技有限责任公司 | Spiro aromatic ring compound and application thereof |
WO2020094018A1 (en) | 2018-11-06 | 2020-05-14 | 上海奕拓医药科技有限责任公司 | Spiro aromatic ring compound and application thereof |
US10844079B2 (en) | 2018-11-06 | 2020-11-24 | Etern Biopharma (Shanghai) Co., Ltd. | Spiro aromatic ring compound and application thereof |
US11685748B2 (en) | 2018-11-06 | 2023-06-27 | Etern Biopharma (Shanghai) Co., Ltd. | Spiro aromatic ring compound and application thereof |
WO2020108590A1 (en) | 2018-11-30 | 2020-06-04 | 上海拓界生物医药科技有限公司 | Pyrimidine and five-membered nitrogen heterocycle derivative, preparation method therefor, and medical uses thereof |
WO2020180768A1 (en) | 2019-03-01 | 2020-09-10 | Revolution Medicines, Inc. | Bicyclic heteroaryl compounds and uses thereof |
WO2020180770A1 (en) | 2019-03-01 | 2020-09-10 | Revolution Medicines, Inc. | Bicyclic heterocyclyl compounds and uses thereof |
US11827644B2 (en) | 2019-03-04 | 2023-11-28 | Suzhou Genhouse Pharmaceutical Co., Ltd | Pyrazine derivative and application thereof in inhibiting SHP2 |
US11696916B2 (en) | 2019-03-07 | 2023-07-11 | Merck Patent Gmbh | Carboxamide-pyrimidine derivatives as SHP2 antagonists |
US11033547B2 (en) | 2019-03-07 | 2021-06-15 | Merck Patent Gmbh | Carboxamide-pyrimidine derivatives as SHP2 antagonists |
US11634417B2 (en) | 2019-04-02 | 2023-04-25 | Array Biopharma Inc. | Protein tyrosine phosphatase inhibitors |
US11884664B2 (en) | 2019-04-02 | 2024-01-30 | Array Biopharma Inc. | Protein tyrosine phosphatase inhibitors |
WO2020201991A1 (en) | 2019-04-02 | 2020-10-08 | Array Biopharma Inc. | Protein tyrosine phosphatase inhibitors |
US11001561B2 (en) | 2019-04-08 | 2021-05-11 | Merck Patent Gmbh | Pyrimidinone derivatives as SHP2 antagonists |
US11702392B2 (en) | 2019-04-08 | 2023-07-18 | Merck Patent Gmbh | Pyrimidinone derivatives as SHP2 antagonists |
WO2020237025A1 (en) | 2019-05-23 | 2020-11-26 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
WO2020263830A1 (en) | 2019-06-25 | 2020-12-30 | Gilead Sciences, Inc. | Flt3l-fc fusion proteins and methods of use |
WO2020259679A1 (en) | 2019-06-28 | 2020-12-30 | 上海拓界生物医药科技有限公司 | Pyrimidine five-membered nitrogen heterocyclic derivative, preparation method thereof and pharmaceutical use thereof |
WO2021028362A1 (en) | 2019-08-09 | 2021-02-18 | Irbm S.P.A. | Shp2 inhibitors |
EP3772513A1 (en) | 2019-08-09 | 2021-02-10 | C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening | Shp2 inhibitors |
WO2021033153A1 (en) * | 2019-08-20 | 2021-02-25 | Otsuka Pharmaceutical Co., Ltd. | Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors |
US11890281B2 (en) | 2019-09-24 | 2024-02-06 | Relay Therapeutics, Inc. | SHP2 phosphatase inhibitors and methods of making and using the same |
WO2021076908A1 (en) | 2019-10-18 | 2021-04-22 | Forty Seven, Inc. | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
EP4349413A2 (en) | 2019-10-18 | 2024-04-10 | Forty Seven, Inc. | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
WO2021087064A1 (en) | 2019-10-31 | 2021-05-06 | Forty Seven, Inc. | Anti-cd47 and anti-cd20 based treatment of blood cancer |
WO2021091982A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
WO2021091967A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
WO2021091956A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
WO2021092115A1 (en) | 2019-11-08 | 2021-05-14 | Revolution Medicines, Inc. | Bicyclic heteroaryl compounds and uses thereof |
US11168102B1 (en) | 2019-11-08 | 2021-11-09 | Revolution Medicines, Inc. | Bicyclic heteroaryl compounds and uses thereof |
WO2021096860A1 (en) | 2019-11-12 | 2021-05-20 | Gilead Sciences, Inc. | Mcl1 inhibitors |
WO2021108683A1 (en) | 2019-11-27 | 2021-06-03 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
WO2021130638A1 (en) | 2019-12-24 | 2021-07-01 | Carna Biosciences, Inc. | Diacylglycerol kinase modulating compounds |
WO2021142026A1 (en) | 2020-01-07 | 2021-07-15 | Revolution Medicines, Inc. | Shp2 inhibitor dosing and methods of treating cancer |
WO2021143701A1 (en) | 2020-01-19 | 2021-07-22 | 北京诺诚健华医药科技有限公司 | Pyrimidine-4(3h)-ketone heterocyclic compound, preparation method therefor and use thereof in medicine and pharmacology |
WO2021163064A2 (en) | 2020-02-14 | 2021-08-19 | Jounce Therapeutics, Inc. | Antibodies and fusion proteins that bind to ccr8 and uses thereof |
US11692038B2 (en) | 2020-02-14 | 2023-07-04 | Gilead Sciences, Inc. | Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8) |
WO2021171261A1 (en) | 2020-02-28 | 2021-09-02 | Novartis Ag | A triple pharmaceutical combination comprising dabrafenib, an erk inhibitor and a shp2 inhibitor |
CN115362149A (en) * | 2020-04-26 | 2022-11-18 | 贝达药业股份有限公司 | SHP2 inhibitor and composition and application thereof |
CN115362149B (en) * | 2020-04-26 | 2024-05-14 | 贝达药业股份有限公司 | SHP2 inhibitor, composition and application thereof |
WO2021218752A1 (en) * | 2020-04-26 | 2021-11-04 | Betta Pharmaceuticals Co., Ltd | Shp2 inhibitors, compositions and uses thereof |
WO2021222522A1 (en) | 2020-05-01 | 2021-11-04 | Gilead Sciences, Inc. | Cd73 inhibiting 2,4-dioxopyrimidine compounds |
WO2021244659A1 (en) | 2020-06-05 | 2021-12-09 | 上海奕拓医药科技有限责任公司 | Isotope-substituted spiro aromatic ring compound and application thereof |
WO2021257736A1 (en) | 2020-06-18 | 2021-12-23 | Revolution Medicines, Inc. | Methods for delaying, preventing, and treating acquired resistance to ras inhibitors |
WO2022060583A1 (en) | 2020-09-03 | 2022-03-24 | Revolution Medicines, Inc. | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
WO2022060836A1 (en) | 2020-09-15 | 2022-03-24 | Revolution Medicines, Inc. | Indole derivatives as ras inhibitors in the treatment of cancer |
WO2022140427A1 (en) | 2020-12-22 | 2022-06-30 | Qilu Regor Therapeutics Inc. | Sos1 inhibitors and uses thereof |
WO2022167682A1 (en) | 2021-02-08 | 2022-08-11 | Irbm S.P.A. | Azabicyclic shp2 inhibitors |
EP4039685A1 (en) | 2021-02-08 | 2022-08-10 | Irbm S.P.A. | Azabicyclic shp2 inhibitors |
EP4067358A1 (en) | 2021-04-02 | 2022-10-05 | C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening | (s)-1-(5-((pyridin-3-yl)thio)pyrazin-2-yl)-4'h,6'h-spiro[piperidine-4,5'-pyrrolo[1,2-b]pyrazol]-4'-amine derivatives and similar compounds as shp2 inhibitors for the treatment of e.g. cancer |
WO2022207924A1 (en) | 2021-04-02 | 2022-10-06 | C.N.C.C.S. S.C.A.R.L. Collezione Nazionale Dei Composti Chimici E Centro Screening | (s)-1-(5-((pyridin-3-yl)thio)pyrazin-2-yl)-4'h,6'h-spiro[piperidine-4,5'-pyrrolo [1,2-b]pyrazol]-4'-amine derivatives and similar compounds as shp2 inhibitors for the treatment of e.g. cancer |
WO2022221304A1 (en) | 2021-04-14 | 2022-10-20 | Gilead Sciences, Inc. | CO-INHIBITION OF CD47/SIRPα BINDING AND NEDD8-ACTIVATING ENZYME E1 REGULATORY SUBUNIT FOR THE TREATMENT OF CANCER |
WO2022235864A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Ras inhibitors |
WO2022235866A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
WO2022235870A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Ras inhibitors for the treatment of cancer |
WO2022245671A1 (en) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Methods of using flt3l-fc fusion proteins |
WO2022259157A1 (en) | 2021-06-09 | 2022-12-15 | Novartis Ag | A triple pharmaceutical combination comprising dabrafenib, trametinib and a shp2 inhibitor |
WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271650A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022269525A1 (en) | 2021-06-23 | 2022-12-29 | Novartis Ag | Pharmaceutical combinations comprising a kras g12c inhibitor and uses thereof for the treatment of cancers |
US12029739B2 (en) | 2021-07-09 | 2024-07-09 | Kanaph Therapeutics Inc. | SHP2 inhibitor and use thereof |
WO2023031781A1 (en) | 2021-09-01 | 2023-03-09 | Novartis Ag | Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers |
WO2023060253A1 (en) | 2021-10-08 | 2023-04-13 | Revolution Medicines, Inc. | Ras inhibitors |
WO2023076983A1 (en) | 2021-10-28 | 2023-05-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
WO2023077030A1 (en) | 2021-10-29 | 2023-05-04 | Gilead Sciences, Inc. | Cd73 compounds |
WO2023107954A1 (en) | 2021-12-08 | 2023-06-15 | Dragonfly Therapeutics, Inc. | Antibodies targeting 5t4 and uses thereof |
WO2023107956A1 (en) | 2021-12-08 | 2023-06-15 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and 5t4 |
WO2023122581A2 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
WO2023122615A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
WO2023122938A1 (en) * | 2021-12-28 | 2023-07-06 | Js Innomed Holdings Ltd. | Heterocyclic compounds as shp2 inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof |
WO2023147418A1 (en) | 2022-01-28 | 2023-08-03 | Gilead Sciences, Inc. | Parp7 inhibitors |
WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
WO2023178181A1 (en) | 2022-03-17 | 2023-09-21 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
EP4245756A1 (en) | 2022-03-17 | 2023-09-20 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
WO2023183817A1 (en) | 2022-03-24 | 2023-09-28 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
WO2023196784A1 (en) | 2022-04-05 | 2023-10-12 | Gilead Sciences, Inc. | Combinations of antibody therapies for treating colorectal cancer |
WO2023205719A1 (en) | 2022-04-21 | 2023-10-26 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
US12097203B2 (en) | 2022-05-04 | 2024-09-24 | Huyabio International, Llc | Combination therapies comprising SHP2 inhibitors and PD-1 inhibitors |
WO2023230205A1 (en) | 2022-05-25 | 2023-11-30 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
WO2024068976A1 (en) | 2022-09-29 | 2024-04-04 | Irbm S.P.A. | Azole derivatives as shp2 inhibitors |
EP4345101A1 (en) | 2022-09-29 | 2024-04-03 | Irbm S.P.A. | Azole derivatives as shp2 inhibitors |
WO2024137852A1 (en) | 2022-12-22 | 2024-06-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3464272B1 (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
TWI697490B (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
CN112409334B (en) | Heterocyclic derivatives useful as SHP2 inhibitors | |
US20240293558A1 (en) | Kras inhibitor conjugates | |
JP2023011889A (en) | Novel heterocyclic derivatives useful as SHP2 inhibitors | |
TWI258471B (en) | Aromatic nitrogen-containing 6-membered cyclic compounds and pharmaceutical composition having phosphodiesterase V inhibitory activity | |
WO2020156243A1 (en) | Shp2 inhibitor and application thereof | |
WO2021057832A1 (en) | Kras mutant protein inhibitor | |
AU2004268948A1 (en) | N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors | |
JP2009532375A (en) | Kinase inhibitor | |
WO2018019252A1 (en) | Novel fused pyridine derivatives useful as fak/aurora kinase inhibitors | |
IL311024A (en) | Substituted tricyclic compounds as parp inhibitors and use thereof | |
WO2023179078A1 (en) | Imidazo [1,2-a] pyrazine or pyrazolo [1,5-a] pyrimidine derivative and use thereof | |
CN115215862A (en) | Pyrimidone compounds and uses thereof | |
WO2022184103A1 (en) | Tricyclic compound and pharmaceutical composition and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17809742 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3026784 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2019517133 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20197000391 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2017809742 Country of ref document: EP Effective date: 20190107 |
|
ENP | Entry into the national phase |
Ref document number: 2017276457 Country of ref document: AU Date of ref document: 20170607 Kind code of ref document: A |